



# Changes to State Controlled Substance Schedules: Bill Status Update

**Research current through June 30, 2015.**

This project was supported by Grant No. G15599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government.

© 2015 Research is current as of June 30, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or [jwoodruff@namsdl.org](mailto:jwoodruff@namsdl.org) with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Federal Schedules	Naloxegol removed from Schedule II.	1/23/2015.
Federal Schedules	The following substances are added to Schedule I: (1) N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)1-(CYCLOHEXYLMETHYL) 1H-INDAZOLE-3-CARBOXAMIDE (AB-CHMINACA); (2) [1-(5-FLUOROPENTYL)-1H-INDAZOL-3-YL] (NAPHTHALEN-1-YL)METHANONE (THJ-2201); (3) N-(1-AMINO-3-METHYL- 1-OXOBUTAN-2-YL)-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE (AB-PINACA).	1/30/2015.
U.S. 2015 HR 1940	“Respect State Marijuana Laws Act of 2015.” Amends the Controlled Substances Act to provide that the provisions related to marihuana “shall not apply to any person acting in compliance with State laws relating to the production, possession, distribution, dispensation, administration, or delivery of marihuana.”	4/22/2015 – introduced and referred to Committees on the Judiciary and Energy and Commerce.
Alabama	No pending proposed regulations. The state’s official controlled substances list is published <a href="#">here</a> and was last updated on January 21, 2015. The controlled substances list is also published as the Appendix to Ala. Admin. Code r. Ch. 420-7-2.	N/A
Alaska 2015 HB 51	Adds tramadol and related substances to Schedule IVA.	1/21/2015 – referred to Judiciary Committee.
Alaska 2015 HB 79	Adds hashish, hash oil and hashish oil to Schedule VIA.	3/9/2015 – hearing in Judiciary Committee scheduled.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Arizona</p> <p>2015 HB 2139 (Page 1 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) Acetylmethadol;</li> <li>(2) 3, 4-methylenedioxy-N-ethylamphetamine (N-ethyl MDA, MDE, MDEA);</li> <li>(3) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy MDA);</li> <li>(4) 5-methoxy-N,N,-dimethyltryptamine (5-MeO-DMT);</li> <li>(5) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);</li> <li>(6) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe, Cimbi-5);</li> <li>(7) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe, Cimbi-82);</li> <li>(8) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe, Cimbi-36);</li> <li>(9) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48);</li> <li>(10) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22);</li> <li>(11) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22);</li> <li>(12) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);</li> <li>(13) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA);</li> <li>(14) Alpha-methylaminovalerophenone (Pentedrone);</li> <li>(15) N-benzylpiperazine (BZP);</li> <li>(16) 3-fluoro-N-methylcathinone (3-FMC);</li> <li>(17) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone);</li> <li>(18) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);</li> <li>(19) 4-methyl-N-ethylcathinone (4-MEC);</li> <li>(20) Naphthypyrovalerone (Naphyrone);</li> <li>(21) N,N-dimethylamphetamine.</li> </ol> <p>Adds the following substances to Schedule II:</p> <ol style="list-style-type: none"> <li>(1) Dihydroetorphine;</li> <li>(2) Oripavine;</li> <li>(3) Fentanyl immediate precursor, 4-anilino-N-phenethyl-4-piperidine (ANPP);</li> <li>(4) Tapentadol.</li> <li>(5) Phenylacetone;</li> </ol>	<p>3/17/2015 – enacted (2015 Laws Chapter 27); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Arizona</p> <p>2015 HB 2139 (Continued) (Page 2 of 3)</p>	<p>Adds the following substances to Schedule II:</p> <p>(6) Lisdexamfetamine, and its salts, isomers and salts of isomers; (7) Nabilone.</p> <p>Removes the following two combination products from Schedule III:</p> <p>(1) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of isoquinoline alkaloid of opium; and (2) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.</p> <p>Adds the following substances to Schedule III:</p> <p>(1) Embutramide; (2) Perampanel, and its salts, isomers and salts of isomers; (3) 3beta, 17-dihydroxy-5a-androstane; (4) 3alpha, 17beta-dihydroxy-5a-androstane; (5) 5alpha-androstan-3, 17-dione; (6) 3beta, 17beta-dihydroxy-5alpha-androst-1-ene; (7) 3alpha, 17beta-dihydroxy-5alpha-androst-1-ene; (8) 4-androstenediol; (9) 5-androstenediol; (10) 1-androstenedione; (11) 4-androstenedione; (12) 5-androstenedione; (13) Bolasterone; (14) Boldione; (15) Calusterone; (16) Desoxymethyltestosterone; (17) Delta1-dihydrotestosterone; (18) 4-dihydrotestosterone; (19) Formebolone; (20) Methasterone; (21) 17alpha-methyl-3beta, 17beta-dihydroxy-5a-androstane; (22) 17alpha-methyl-3alpha, 17beta-dihydroxy-5a-androstane; (23) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene; (24) 17alpha-methyl-4-hydroxynandrolone;</p>	<p>3/17/2015 – enacted (2015 Laws Chapter 27); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Arizona</p> <p>2015 HB 2139 (Continued) (Page 3 of 3)</p>	<p>Adds the following substances to Schedule III:</p> <ul style="list-style-type: none"> <li>(25) Methyldienolone;</li> <li>(26) Methyltrienolone;</li> <li>(27) 17alpha-methyl-delta1-dihydrotestosterone;</li> <li>(28) 3beta, 17beta-dihydroxyestr-4-ene;</li> <li>(29) 3alpha, 17beta-dihydroxyestr-4-ene;</li> <li>(30) 3beta, 17beta-dihydroxyestr-5-ene;</li> <li>(31) 3alpha, 17beta-dihydroxyestr-5-ene;</li> <li>(32) 19-nor-4,9(10)-androstadienedione;</li> <li>(33) 19-nor-4-androstenedione;</li> <li>(34) 19-nor-5-androstenedione;</li> <li>(35) Norbolethone;</li> <li>(36) Norclostebol;</li> <li>(37) Normethandrolone;</li> <li>(38) Prostanazol;</li> <li>(39) Stenbolone;</li> <li>(40) Tetrahydrogestrinone;</li> <li>(41) Dronabinol, (synthetic delta-9-tetrahydrocannabinol) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product.</li> </ul> <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) Modafinil;</li> <li>(2) Sibutramine;</li> <li>(3) Alfaxalone</li> <li>(4) Fospropofol.</li> <li>(5) Suvorexant</li> <li>(6) Zopiclone</li> <li>(7) Lorcaserin,</li> </ul> <p>Adds the following substances to Schedule V:</p> <ul style="list-style-type: none"> <li>(1) Ezogabine;</li> <li>(2) Lacosamide;</li> <li>(3) Pregabalin.</li> </ul>	<p>3/17/2015 – enacted (2015 Laws Chapter 27); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Arkansas</p> <p>Ark. Admin. Code 007.07.2</p>	<p>Revised schedules effective 5/25/2015 contain the following changes as compared to schedules effective 7/23/2014:</p> <p>The following substances are added to Schedule I:</p> <ul style="list-style-type: none"> <li>(1) Etizolam;</li> <li>(2) 1-(1,3-benzodioxol-5-yl)-2-methylamino) butan-1-one (Butylone).</li> </ul> <p>The following substances are added to Schedule III:</p> <ul style="list-style-type: none"> <li>(1) Perampanel;</li> <li>(2) Prostanazol;</li> <li>(3) Methasterone.</li> </ul> <p>The following combination products are removed from Schedule III:</p> <ul style="list-style-type: none"> <li>(1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> <li>(2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts.</li> </ul> <p>Alfaxalone is added to Schedule IV.</p> <p>MAB-CHMINCA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide is added to Schedule VI.</p>	<p>5/25/2015 – regulation adopted.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California  2015 SB 139 (Page 1 of 10)	<p>Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:</p> <p>(1) Adamantoylindoles or adamantoylindazoles, which includes adamantyl carboxamide indoles and adamantyl carboxamide indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3- (1-adamantoyl)indazole, 3-(2-adamantoyl)indole, N- (1-adamantyl)-1H-indole-3-carboxamide, or N- (1-adamantyl)-1H-indazole-3-carboxamide by substitution at the nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including, but not limited to, 2NE1, 5F-AKB-48, AB-001, AKB-48, AM-1248, JWH-018 adamantyl carboxamide, STS-135.</p> <p>(2) Benzoylindoles, which includes any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including, but not limited to, AM-630, AM-661, AM-679, AM-694, AM-1241, AM-2233, RCS-4, WIN 48,098 (Pravadoline).</p>	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
California  2015 SB 139 (Continued) (Page 2 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:  (3) Cyclohexylphenols, which includes any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the cyclohexyl ring to any extent, including, but not limited to, CP 47,497, CP 55,490, CP 55,940, CP 56,667, cannabicyclohexanol.  (4) Cyclopropanoylindoles, which includes any compound structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-(cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent.	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
California  2015 SB 139 (Continued) (Page 3 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:  (5) Naphthoylindoles, which includes any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl- (1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl,haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1- (N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to any extent, including, but not limited to AM-678, AM-1220, AM-1221, AM-1235, AM-2201, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081,JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55,212.  (6) Naphthoylnaphthalenes, which includes any compound structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent, including, but not limited to, CB-13.	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
California  2015 SB 139 (Continued) (Page 4 of 10)	<p>Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:</p> <p>(7) Naphthoylpyrroles, which includes any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including, but not limited to, JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392.</p> <p>(8) Naphthylmethylindenes, which includes any compound containing a naphthylideneindene structure or which is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including, but not limited to, JWH-171, JWH-176, JWH-220.</p>	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California  2015 SB 139 (Continued) (Page 5 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances  (9) Naphthylmethylindoles, which includes any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2- (4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1- (N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including, but not limited to, JWH-175, JWH-184, JWH-185, JWH-192, JWH-194, JWH-195, JWH-196, JWH-197, JWH-199.  (10) Phenylacetylindoles, which includes any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1- (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including, but not limited to, cannabipiperidiethanone, JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8.	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
California  2015 SB 139 (Continued) (Page 6 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: (11) Quinolinyndolecarboxylates, which includes any compound structurally derived from quinolin-8-yl-1H-indole-3-carboxylate by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2- (4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the quinoline ring to any extent, including, but not limited to, BB-22, 5-Fluoro-PB-22, PB-22.  (12) Tetramethylcyclopropanoylindoles, which includes any compound structurally derived from 3-tetramethylcyclopropanoylindole, 3- (1-tetramethylcyclopropyl)indole, 3- (2,2,3,3-tetramethylcyclopropyl)indole or 3- (2,2,3,3-tetramethylcyclopropylcarbonyl)indole with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1- (N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropanoyl ring to any extent, including, but not limited to, 5-bromo-UR-144, 5-chloro-UR-144, 5-fluoro-UR-144, A-796,260, A-834,735, AB-034, UR-144, XLR11.	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California  2015 SB 139 (Continued) (Page 7 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances:  (13) Tetramethylcyclopropane-thiazole carboxamides, which includes any compound structurally derived from 2,2,3,3-tetramethyl-N- (thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including, but not limited to, A-836,339.  (14) Unclassified synthetic cannabinoids, which includes all of the following: a. (A) AM-087, (6aR,10aR)-3- (2-methyl-6-bromohex-2-yl)-6,6,9-trimethyl-6 a,7,10,10a-tetrahydrobenzoc]chromen-1-ol; b. AM-356, Methanandamide, including (5Z,8Z,11Z,14Z)-N-(1R)-2-hydro xy-1-methylethyl]icosa-5,8,11,14-tetraenamide and arachidonyl-1?-hydroxy-2?-propylamide; c. AM-411, (6aR,10aR)-3- (1-adamantyl)-6,6,9-trimethyl-6a,7,10,10a-te trahydrobenzoc]chromen-1-ol; d. (D) AM-855, (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-o ctahydronaphtho3,2-c]isochromen-12-ol; e. (E) AM-905, (6aR,9R,10aR)-3-(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-d imethyl-6a,7,8,9,10,10a-hexahydrobenzoc]chromen-1-ol; f. AM-906, (6aR,9R,10aR)-3-(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-d imethyl-6a,7,8,9,10,10a-hexahydrobenzoc]chromen-1-ol;	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
California  2015 SB 139 (Continued) (Page 8 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: <ul style="list-style-type: none"> <li>g. AM-2389, (6aR,9R,10aR)-3- (1-hexyl-cyclobut-1-yl)-6a,7,8,9,10,10a- hexahydro-6,6-dimethyl-6H-dibenzob,d]pyran-1,9 diol;</li> <li>h. (H) BAY 38-7271, (-)-(R)-3- (2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4 -trifluorobutyl-1-sulfonate;</li> <li>i. CP 50,556-1, Levonantradol, including 9-hydroxy-6-methyl-3-5-phe nylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]ace etate; (6S,6aR,9R, 10aR)-9-hydroxy-6-methyl-3-(2R)-5-ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; and 9-hydroxy-6-methyl-3-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate;</li> <li>j. HU-210, including (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- (2- methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzoc] chromen-1-ol; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyl octan-2-yl)-6a,7,10,10a-tetrahydrobenzoc]chromen-1-ol and 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol;</li> <li>k. HU-211, Dexanabinol, including (6aS, 10aS)-9-(hydroxymethyl)-6,6- dimethyl-3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzoc]chromen-1-ol and (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl- 3- (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzoc]chromen-1-ol;</li> <li>l. HU-243, 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;</li> <li>m. HU-308, (91R,2R,5R)-2-2,6-dimethoxy-4- (2-methyloctan-2-yl)pheny l]-7,7-dimethyl-4-bicyclo3.1.1]hept-3-enyl]methanol;</li> <li>n. HU-331, 3-hydroxy-2-(1R,6R)-3-methyl-6- (1-methylethenyl)-2-cyclo hexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione;</li> </ul>	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
California  2015 SB 139 (Continued) (Page 9 of 10)	Amends definition of “synthetic cannabinoid compound” under state’s Controlled Substances Act to refer to the following substances: <ul style="list-style-type: none"> <li>o. HU-336, (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydr o-1H-benzoc]chromene-1,4(6H)-dione;</li> <li>p. JTE-907, N- (benzol1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-penty loxy-1,2-dihydroquinoline-3-carboxamide;</li> <li>q. JWH-051, ((6aR,10aR)-6,6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzoc]chromen-9-yl)methanol;</li> <li>r. JWH-057 (6aR,10aR)-3- (1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro- 6,6,9-trimethyl-6H-Dibenzob,d]pyran;</li> <li>s. JWH-133 (6aR,10aR)-3- (1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H-dibenzob,d]pyran;</li> <li>t. JWH-359, (6aR,10aR)- 1-methoxy- 6,6,9-trimethyl- 3-(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzoc]chromene;</li> <li>u. URB-597 3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate;</li> <li>v. URB-602 1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; OR cyclohexyl 1,1'-biphenyl]-3-ylcarbamate;</li> <li>w. URB-754 6-methyl-2- (4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one;</li> <li>x. URB-937 3'-carbamoyl-6-hydroxy-1,1'-biphenyl]-3-yl cyclohexylcarbamate;</li> <li>y. WIN 55,212-2, including (R)-(+)-2,3-dihydro-5-methyl-3-(4-morpho linylmethyl)pyrrolo1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethano one and 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo (1,2,3-de)-1,4-ben zoxazin-6-yl]-1-napthalenylmethanone.</li> </ul>	5/13/2015 – first hearing cancelled at request of author.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
California  2015 SB 139 (Continued) (Page 10 of 10)	Amends the definition of “synthetic stimulant compound” under state’s Controlled Substances Act to refer to the following substances:  “Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, subdivisions (a) and (b) apply to any material, compound, mixture, or preparation which contains any quantity of a substance, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers whenever the existence of such salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers is possible, that is structurally derived from 2-amino-1-phenyl-1-propanone by modification in one of the following ways:  (1) By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents. (2) By substitution at the 3-position with an alkyl substituent. (3) By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.	5/13/2015 – first hearing cancelled at request of author.
Colorado	No pending proposed legislation.	
Connecticut	No pending proposed regulations. The regulations were last updated in September 2013.	
Delaware	No pending proposed legislation.	
District of Columbia  2015 LB 23	The legislation is the “Marijuana Legalization and Regulation Act of 2015.” Among many other things, it provides that hashish is a Schedule II controlled substance “only as it relates to D.C. Official Code § 50-2206.01 for the purpose of defining controlled substances as they relate only to driving under the influence of drugs.”  Also provides that cannabis is a Schedule III controlled substance “only when it relates to . . . [d]riving or boating under the influence of drugs pursuant to D.C. Official Code § 50-2206.01.”	2/9/2015 – public hearing.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Florida 2015 HB 287	Amended in committee to require Florida Attorney General to make a recommendation for the scheduling of Kratom ( <i>mitragyna speciosa</i> ).	4/28/2015 – died in committee.
Florida 2015 HB 897	Adds the following substances to Schedule I: (1) AB-CHMINACA: N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (2) FUB-PB-22: Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate; (3) Fluoro-NNEI: 1-(Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide; (4) Fluoro-AMB: Methyl 2-(1-(fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; (5) THJ-2201: [1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone.	5/14/2015 – enacted (2015 Laws Chapter 34); effective 5/14/2015.
Florida 2015 HB 4041	Removes cannabis from schedule of controlled substances.	4/28/2015 – died in committee.
Florida 2015 SB 764	Adds “Mitragynine or 7-Hydroxymitragynine, except for any drug product approved by the United States Food and Drug Administration which contains Mitragynine or 7 Hydroxymitragynine, including any of their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation” to Schedule I.	5/1/2015 – died in committee.
Florida 2015 SB 1098	Adds the following substances to Schedule I: (1) AB-CHMINACA: N-[1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (2) FUB-PB-22: Quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole 3-carboxylate; (3) Fluoro-NNEI: 1-(Fluoropentyl)-N-(naphthalen-1-yl)-1H indole-3-carboxamide; (4) 5-Fluoro-AMB: Methyl 2-(1-(fluoropentyl)-1H-indazole 3-carboxamido)-3-methylbutanoate; (5) THJ-2201: [1-(5-Fluoropentyl)-1H-indazol-3 yl](naphthalen-1-yl)methanone.	4/23/2015 – substituted by 2015 HB 897.
Florida 2015 SB 1294	Removes cannabis from schedule of controlled substances.	5/1/2015 – died in committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Georgia</p> <p>2015 HB 211</p>	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) 3-(1,3-benzenodioxol-5-yl)-N,2-dimethylpropan-1-amine (3,4-methylenedioxymethamphetamine methyl homolog);</li> <li>(2) (2-aminopropyl)-2,3-dihydrobenzofuran (APDB);</li> <li>(3) 4-methyl-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25D-NBOMe);</li> <li>(4) 2-chloro-4,5-methylenedioxymethamphetamine;</li> <li>(5) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);</li> <li>(6) 2-bromo-4,5-methylenedioxymethamphetamine;</li> <li>(7) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe);</li> <li>(8) Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201);</li> <li>(9) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144);</li> <li>(10) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);</li> <li>(11) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone (THJ 018).</li> </ol> <p>Removes the following combination products from Schedule III:</p> <ol style="list-style-type: none"> <li>(1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> <li>(2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</li> </ol> <p>Adds the following substances to Schedule IV:</p> <ol style="list-style-type: none"> <li>(1) Alfaxalone;</li> <li>(2) Etizolam;</li> <li>(3) Phenazepam;</li> <li>(4) Suvorexant.</li> </ol>	<p>5/6/2015 – enacted (2015 Laws Chapter 125); effective 5/6/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Hawaii 2015 HB 331	Adds nicotine to the substances listed in Schedule V.	1/26/2015 – introduced and referred to Committees on Judiciary and Health.
Hawaii 2015 HB 841	Among other things, removes the following from Schedule I: (1) Marijuana; (2) Tetrahydrocannabinols.	1/28/2015 – introduced and referred to Committees on Judiciary and Health.
Hawaii 2015 HB 889	Among other things, removes the following from Schedule I: (1) Marijuana; (2) Tetrahydrocannabinols.	1/28/2015 – introduced and referred to Committees on Judiciary and Health.
Hawaii 2015 HB 962	Removes the following combination products from Schedule III: (1) Not more than 300 milligrams of dihydrocodeinone (Hydrocedene), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium provided that these narcotic drugs shall be monitored pursuant to section 329-101; (2) Not more than 300 milligrams of dihydrocodeinone (Hydrocodone), or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognised therapeutic amounts provided that these narcotic drugs shall be monitored pursuant to section 329-101;  Adds the following to Schedule IV. (1) Suvorexant; (2) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol).	1/29/2015 – introduced and referred to Committees on Judiciary and Health.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Hawaii  2015 SB 189	Removes marijuana and its intrinsic cannabinoids from Schedule I and requires the state Department of Public Safety, in consultation with the state Department of Health, to issue a recommendation for the rescheduling of marijuana.	2/26/2015 – Measure deferred by Committee on Judiciary and Labor.
Hawaii  2015 SB 383	Among other things, removes the following from Schedule I: (1) Marijuana; (2) Tetrahydrocannabinols.	1/26/2015 – Referred to House Committee on Public Safety and Military Affairs; referred to Senate Committees on Judiciary and Labor and Ways and Means.
Hawaii  2015 SB 1131 (Page 1 of 2)	Adds the following substances to Schedule I: (1) 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine; (2) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-CHMINACA); (3) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA); (4) (naphthalen-1-yl)methanone, and geometric isomers, salts, and salts of isomers (Other names: THJ-2201); (5) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, and geometric isomers, salts, and salts of isomers (other names: FUB-AMB);	6/29/2015 – not on Governor's intent to veto list; will become law with or without Governor's signature by 7/14/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Hawaii</p> <p>2015 SB 1131 (Continued) (Page 2 of 2)</p>	<p>Adds the following substances to Schedule I:</p> <p>(6) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB, 5-fluoro-AMP);</p> <p>(7) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AKB48 N-(5-fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl analog, 5F-APINACA);</p> <p>(8) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and geometric isomers, salts, and salts of isomers (Other names: STS-135, 5F-APICA; 5-fluoro-APICA);</p> <p>(9) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, and geometric isomers, salts, and salts of isomers (Other names: NM2201).</p> <p>Removes the following combination products from Schedule III:</p> <p>(1) Not more than 300 milligrams of dihydrocodeinone (Hydrocodone), or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium provided that these narcotic drugs shall be monitored pursuant to section 329-101;</p> <p>(2) Not more than 300 milligrams of dihydrocodeinone (Hydrocodone), or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts provided that these narcotic drugs shall be monitored pursuant to section 329-101;</p> <p>Adds the following to Schedule IV.</p> <p>(1) Suvorexant;</p> <p>(2) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol).</p>	<p>6/29/2015 – not on Governor’s intent to veto list; will become law with or without Governor’s signature by 7/14/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Idaho</p> <p>2015 HB 9</p>	<p>Adds Perampanel and its salts, isomers and salts of isomers to Schedule III.</p> <p>Removes the following combination products from Schedule III:</p> <p>(1) Not more than 300 milligrams of dihydrocodeinone, commonly known as hydrocodone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</p> <p>(2) Not more than 300 milligrams of dihydrocodeinone, commonly known as hydrocodone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p> <p>Adds the following substances to Schedule IV:</p> <p>(1) 2- [(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol (including tramadol), including its salts, optical and geometric isomers, and salts of isomers;</p> <p>(2) Quazepam;</p> <p>(3) Suvorexant.</p>	<p>3/5/2015 – enacted (2015 Laws Chapter 29); effective 3/5/2015.</p>
<p>Illinois</p> <p>2015 HB 1497</p>	<p>Adds alpha-Pyrrolidinopentiophenone to Schedule I.</p>	<p>3/27/2015 – re-referred to Rules Committee.</p>
<p>Illinois</p> <p>2015 HB 3588</p>	<p>Adds provision to Schedule I that “if the Department [of Human Services] adopts an emergency rule under Section 10 of the Synthetic Drug Identification Pilot Program Act adding a synthetic drug to the list of Schedule I controlled substances that drug shall be automatically added as a Schedule I controlled substance upon the effective date of the emergency rule.”</p>	<p>4/24/2015 – re-referred to Rules Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1129 (Page 1 of 5)	Adds the following substances to Schedule I: (1) Trifluoromethylphenylpiperazine (TFMPP); (2) Any compound structurally derived from 3-(1-naphthoyl) indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; (3) Any compound structurally derived from 3-(1-naphthoyl) pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; (4) Any compound structurally derived from 1-(1-naphthylmethyl) indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl) ethyl whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-176; (5) Any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-167, JWH-250, JWH-251, and RCS-8;	6/18/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1129 (Continued) (Page 2 of 5)	Adds the following substances to Schedule I: (6) Any compound structurally derived from 2-(3-hydroxycyclohexyl) phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl)ethyl, whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); (7) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; (8) 3-cyclopropoylindole with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the cyclopropyl ring to any extent: including but not limited to XLR11, UR144, FUB-144; (9) 3-adamantoylindole with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent: including but not limited to AB-001;	6/18/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1129 (Continued) (Page 3 of 5)	Adds the following substances to Schedule I: (10) N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent: including but not limited to APICA/2NE-1, STS-135; (11) N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent: including but not limited to AKB48, 5F-AKB48; (12) 1H-indole-3-carboxylic acid 8-quinolinyl ester with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the quinoline ring to any extent: including but not limited to PB22, 5F-PB22, FUB-PB-22; (13) 3-(1-naphthoyl)indazole with substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent: including but not limited to THJ-018, THJ-2201;	6/18/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1129 (Continued) (Page 4 of 5)	Adds the following substances to Schedule I: (14) 2-(1-naphthoyl)benzimidazole with substitution at the nitrogen atom of the benzimidazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the benzimidazole ring to any extent, whether or not substituted on the naphthyl ring to any extent: including, but not limited to FUBIMINA; (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including but not limited to AB-PINACA, AB-FUBINACA, AB-CHMINACA; (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including but not limited to ADB-PINACA, ADB-FUBINACA; (17) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indole-3-carboxamide with substitution on the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent: including but not limited to ADBICA, 5F-ADBICA; (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-3-carboxamide with substitution on the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent: including but not limited to ABICA, 5F-ABICA;	6/18/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Illinois</p> <p>2015 SB 1129 (Continued) (Page 5 of 5)</p>	<p>Adds the following substances to Schedule I:</p> <p>(19) Methyl 2-(1H-indazole-3-carboxamido)-3-methylbutanoate with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including but not limited to AMB, 5F-AMB.</p> <p>Synthetic cathinones. Unless specifically excepted, any chemical compound not including bupropion, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or more of the following ways:</p> <p>(1) by substitution in the ring system to any extent with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4-Methylenedioxcathinone (bk-MDA);</p> <p>(2) by substitution at the 3-position with an acyclic alkyl substituent. Examples of this class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); or</p> <p>(3) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and a-Pyrrolidinopropiophenone (a-PPP).</p>	<p>6/18/2015 – enrolled bill sent to Governor.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1282 (Page 1 of 4)	Adds the following substances to Schedule I:  Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical compound which is not approved by the United States Food and Drug Administration or, if approved, which is not dispensed or possessed in accordance with State and federal law, that contains: <ol style="list-style-type: none"> <li>(1) Benzylpiperazine (BZP);</li> <li>(2) Trifluoromethylphenylpiperazine (TFMPP);</li> <li>(3) 1,1- Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1-Pentyl-3-(1-naphthoyl) indole;</li> <li>(4) dexanabinol (HU-211); or</li> <li>(5) any compound in the following structural classes:               <ol style="list-style-type: none"> <li>a. Naphthylmethyloindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-175, JWH-184, and JWH-185;</li> <li>b. Phenylacetyloindoles: Any compound containing a 3-phenylacetyloindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-167, JWH-250, JWH-251, and RCS-8;</li> </ol> </li> </ol>	5/15/2015 – third reading deadline established as 5/31/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1282 (Continued) (Page 2 of 4)	Adds the following substances to Schedule I:  c. Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4;  d. Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol);  e. Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-175, JWH-184, and JWH-185;  f. Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368	5/15/2015 – third reading deadline established as 5/31/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1282 (Continued) (Page 3 of 4)	<p>Adds the following substances to Schedule I:</p> <p>g. Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-176;</p> <p>h. Any other synthetic cannabinoid or piperazine which is not approved by the United States Food and Drug Administration or, if approved, which is not dispensed or possessed in accordance with State and federal law.</p> <p>Synthetic cathinones. Unless specifically excepted, any chemical compound which is not approved by the United States Food and Drug Administration or, if approved, which is not dispensed or possessed in accordance with State and federal law, not including bupropion, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or more of the following ways:</p> <p>(1) By substitution in the ring system to any extent with alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4-Methylenedioxcathinone (bk-MDA);</p>	<p>5/15/2015 –  <a href="#">third reading deadline established as 5/31/2015.</a></p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Illinois  2015 SB 1282 (Continued) (Page 4 of 4)	Adds the following substances to Schedule I: (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and a-Pyrrolidinopropiophenone (a-PPP); (4) Any other synthetic cathinone which is not approved by the United States Food and Drug Administration or, if approved, is not dispensed or possessed in accordance with State or federal law.	5/15/2015 – third reading deadline established as 5/31/2015.
Indiana  2015 HB 1184	Removes the following combination products from Schedule III: (1) Not more than 300 milligrams of dihydrocodeinone, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium. (2) Not more than 300 milligrams of dihydrocodeinone, per 100 milliliters or not more than 15 milligrams per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts.  Adds Tramadol (Ultram) to Schedule IV.	4/23/2015 – enacted (2015 Laws Chapter 56); effective 4/23/2015.
Indiana  2015 HB 1382	Adds Ephedrine and Pseudoephedrine to Schedule III.	1/14/2015 – first reading; referred to Committee on Public Health.
Indiana  2015 HB 1602	Among other things, adds Ephedrine and Pseudoephedrine to Schedule IV.	1/20/2015 – first reading and referred to Committee on Courts and Criminal Code.

Yellow highlighted text indicates legislation that has been enacted into law.  
 Red text indicates that the legislature presently is not in session.  
 Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Indiana  2015 SB 290	Adds Ephedrine and Pseudoephedrine to Schedule III.	1/8/2015 – first reading and referred to Committee on Corrections & Criminal Law.
Indiana  2015 SB 445	Adds the following provision to Schedule IV:  This subsection applies from July 1, 2015, through June 30, 2018. Except for a product that has been found by the Indiana board of pharmacy to be an extraction resistant or conversion resistant form of ephedrine or pseudoephedrine under IC 25-26-13-4.2, a material, compound, mixture, or preparation that contains a quantity of any of the following substances, pure or adulterated: (1) Ephedrine. (2) Pseudoephedrine.	1/14/2015 – reassigned to Committee on Corrections & Criminal Law.
Indiana  2015 SB 536	Adds the following provision to Schedule IV:  “This subsection applies from July 1, 2020, through June 30, 2023, unless the superintendent of the state police department has submitted a report under IC 10-11-2-34 showing that four hundred (400) or fewer methamphetamine laboratories were discovered in Indiana during calendar year 2019. Except for a product that has been found by the Indiana board of pharmacy to be an extraction resistant or conversion resistant form of ephedrine or pseudoephedrine under IC 25-26-13-4.2, a material, compound, mixture, or preparation that contains a quantity of any of the following substances, pure or adulterated: (1) Ephedrine. (2) Pseudoephedrine.”.	3/5/2015 – first reading in House; referred to Committee on Courts and Criminal Code.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Iowa</p> <p>2015 HF 567 (Page 1 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> <li>(1) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);</li> <li>(2) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);</li> <li>(3) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);</li> <li>(4) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);</li> <li>(5) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);</li> <li>(6) 2-(2,5-Dimethoxyphenyl) ethanamine (2C-H);</li> <li>(7) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N);</li> <li>(8) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);</li> <li>(9) HU-210. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 6a,7,10,10a] tetrahydrobenzo[c] chromen-1-ol];</li> <li>(10) HU-211(dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol).</li> </ul> <p>Adds the following new paragraph to Schedule I:</p> <p>“Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.</p> <ul style="list-style-type: none"> <li>(1) The term "cannabimimetic agents" means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes: <ul style="list-style-type: none"> <li>a. 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.</li> <li>b. 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.</li> </ul> </li> </ul>	<p>5/5/2015 – passed Senate.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Iowa</p> <p>2015 HF 567 (Continued) (Page 2 of 3)</p>	<p>Adds the following new paragraph to Schedule I:</p> <ul style="list-style-type: none"> <li>c. 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.</li> <li>d. 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.</li> <li>e. 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.</li> </ul> <p>(2) Such terms include:</p> <ul style="list-style-type: none"> <li>a. (a) CP 47,497 and homologues 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]phenol;</li> <li>b. JWH-018 and AM678 1-Pentyl-3-(1-naphthoyl)indole;</li> <li>c. JWH-073 1-Butyl-3-(1-naphthoyl)indole;</li> <li>d. JWH-200[1-[2-(4-morpholinyl)ethyl]-1H26 indol-3-yl]-1-naphthalenyl-methanone;</li> <li>e. JWH-19 1-hexyl-3-(1-naphthoyl)indole;</li> <li>f. JWH-81 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole;</li> <li>g. JWH-122 1-pentyl-3-(4-methyl-1-naphthoyl)indole;</li> <li>h. JWH-250 1-pentyl-3-(2-methoxyphenylacetyl)indole;</li> <li>i. RCS-4 and SR-19 1-pentyl-3-[(4methoxy)-benzoyl]indole;</li> <li>j. RCS-8 and SR 18 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole;</li> <li>k. AM2201 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;</li> <li>l. JWH-203 1-pentyl-3-(2-chlorophenylacetyl)indole;</li> <li>m. JWH-398 1-pentyl-3-(4-chloro-1-naphthoyl)indole;</li> <li>n. AM694 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;</li> <li>f. Cannabicyclohexanol or CP-47,497 C8-homolog 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol.</li> </ul>	<p>5/5/2015 – passed Senate.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Iowa</p> <p>2015 HF 567 (Continued) (Page 3 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <p>(1) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- fluorobenzyl)-1H-indazole-3-carboxamide. Other names: AB-FUBINACA;</p> <p>(2) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1 H-indazole-3-carboxamide. Other names: ADB-PINACA;</p> <p>(3) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate. Other names: PB-22, QUPIC;</p> <p>(4) Quinolin-8-yl 1-(5-fluoropentyl)- 1H-indole-3-carboxylate. Other names: 5-fluoro-PB-22, 5F-PB-22;</p> <p>(5) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide. Other names: AB-PINACA;</p> <p>(6) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl) -1H-indazole-3-carboxamide. Other names: AB-CHMINACA;</p> <p>(7) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone. Other names: THJ-2201.</p> <p>Adds the following to Schedule III: 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers (including tramadol).</p> <p>Adds Alfaxalone and Suvorexant to Schedule IV.</p>	<p>5/5/2015 – passed Senate.</p>
<p>Iowa</p> <p>2015 SF 282</p>	<p>Moves marijuana, including tetrahydrocannabinols, from Schedule I to Schedule II.</p>	<p>2/19/2015 – introduced; referred to Human Resources Committee.</p>
<p>Iowa</p> <p>2015 SF 484</p>	<p>“Medical Cannabis Act.” Among other things, moves marijuana, including tetrahydrocannabinols, from Schedule I to Schedule II.</p>	<p>4/15/2015 – read first time in House; referred to Public Safety Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Iowa  2015 SF 510 (Page 1 of 2)	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) 4-methyl-N-ethylcathinone. Other names: 4-MEC, 2-(ethylamino)-1-(4-methylphenyl)propan-1-one;</li> <li>(2) 4-methyl-alpha34 pyrrolidinopropiophenone. Other names: 4-MePPP, MePPP, 4-methyl-[alpha]-pyrrolidinopropiophenone, 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one;</li> <li>(3) Alpha-pyrrolidinopentiophenone. Other names: [alpha]-PVP, [alpha]-pyrrolidinovalerophenone, 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one;</li> <li>(4) Butylone. Other names: bk-MBDB, 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one;</li> <li>(5) Pentedrone. Other names: [alpha]-methylaminovalerophenone, 2-(methylamino)-1-phenylpentan-1-one;</li> <li>(6) Pentylone. Other names: bk-MBDP, 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one;</li> <li>(7) 4-fluoro-N-methylcathinone. Other names: 4-FMC, flephedrone, 1-(4-fluorophenyl)-2-(methylamino)propan-1-one;</li> <li>(8) 3-fluoro-N-methylcathinone. Other names: 3-FMC, 1-(3-fluorophenyl)-2-(methylamino)propan-1-one;</li> <li>(9) Naphyrone. Other names: naphthylpyrovalerone, 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one;</li> <li>(10) Alpha-pyrrolidinobutiophenone. Other names: [alpha]-PBP, 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one;</li> <li>(11) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate. Other names: PB-22, QUPIC;</li> <li>(12) Quinolin-8-yl 1-(5-fluoropentyl)-1H27 indole-3-carboxylate. Other names: 5-fluoro-PB-22, 5F-PB-22.;</li> <li>(13) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide. Other name: AB-FUBINACA;</li> <li>(14) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide. Other name: ADB-PINACA.</li> </ol>	6/5/2015 – passed House.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Iowa</p> <p>2015 SF 510 (Page 2 of 2)</p>	<p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> <li>(1) Not more than three hundred milligrams of dihydrocodeinone (another name: hydrocodone) per one hundred milliliters or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.</li> <li>(2) Not more than three hundred milligrams of dihydrocodeinone (another name: hydrocodone) per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</li> </ul> <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers (including tramadol);</li> <li>(2) Alfaxalone;</li> <li>(3) Suvorexant.</li> </ul>	<p>6/5/2015 – passed House.</p>
<p>Kansas</p> <p>2015 HB 2275 (Page 1 of 2)</p>	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> <li>(1) 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl) ethanamine Some trade or other names: 25D-NBOMe; 2C-D-NBOMe;</li> <li>(2) (1H-indazol-3-yl)methanones. Any compound containing a (1H-indazol-3-yl)methanone structure with the carbonyl carbon bearing a naphthyl group and substitution at the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted on the indazole ring to any extent and whether or not substituted on the naphthyl or benzyl groups to any extent.</li> </ul> <p>Moves the following combination product from Schedule III to Schedule II:</p> <ul style="list-style-type: none"> <li>(1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> </ul>	<p>4/8/2015 – enacted (2015 Laws Chapter 27); effective 4/16/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Kansas</p> <p>2015 HB 2275 (Continued) (Page 2 of 2)</p>	<p>Moves the following combination product from Schedule III to Schedule II:</p> <p>(2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) or any of its salts per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</p> <p>Adds Perampanel, its salts, isomers, and salts of isomers [Some other names for perampanel: 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl) benzonitrile] to Schedule III.</p> <p>Adds the following substances to Schedule IV:</p> <p>(1) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol)</p> <p>(2) Alfaxalone</p> <p>(3) Suvorexant.</p>	<p>4/8/2015 – enacted (2015 Laws Chapter 27); effective 4/16/2015.</p>
<p>Kentucky</p> <p>2015 HB 32</p>	<p>Adds Acetylfentanyl to Schedule I.</p>	<p>1/6/2015 – introduced.</p>
<p>Kentucky</p> <p>2015 HB 51</p>	<p>Adds the following substance to Schedule I: “Any extended release single-agent formulation of hydrocodone bitartrate that does not contain tamper-resistant or tamper-deterrent countermeasures as approved by the federal Food and Drug Administration.”</p>	<p>1/6/2015 – introduced.</p>
<p>Kentucky</p> <p>2015 HB 53</p>	<p>Adds the following substance to Schedule I: “Any extended release single-agent formulation of hydrocodone bitartrate, including the drug Zohydro, that does not contain tamper-resistant or tamper-deterrent countermeasures as approved by the federal Food and Drug Administration.”</p>	<p>1/6/2015 – introduced.</p>
<p>Kentucky</p> <p>2015 HB 213</p>	<p>Among other provisions, adds Acetylfentanyl to Schedule I.</p>	<p>2/20/2015 – referred to Senate Judiciary Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Kentucky  2015 HB 412	Among other provisions, adds Acetylfentanyl to Schedule I.	3/24/2015 – passed over and retained in orders of the day.
Kentucky  2015 SB 192	Among other provisions, adds Acetylfentanyl to Schedule I.	3/25/2015 – enacted (2015 Laws Chapter 66); effective 3/25/2015.
Louisiana  2015 HB 72 (Page 1 of 2)	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);</li> <li>(2) N-(2-methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe);</li> <li>(3) (2-methylaminopropyl)benzofuran (5-MAPB);</li> <li>(4) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-Hydroxy-MIPT);</li> <li>(5) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)butan-1-one (Alpha-PBT)</li> <li>(6) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (Alpha-PVT);</li> <li>(7) Naphthylindole carboxylates: Any compound containing a naphthyl-1H-indole-3-carboxylate structure, whether or not further substituted in the indole ring or the naphthyl ring to any extent;</li> <li>(8) Benzylindolecarboxamides: Any compound containing a N-benzyl-1H-indole-3-carboxamide structure, whether or not further substituted in the indole ring or the phenyl ring to any extent;</li> <li>(9) Quinolinyndolecarboxamides: Any compound containing a N-quinolinyndole-1H-indole-3-carboxamide or N-isoquinolinyndole-1H-indole-3-carboxamide structure, whether or not further substituted in the indole, quinoline or the isoquinoline ring to any extent;</li> <li>(10) Phenylindolecarboxamides: Any compound containing a N-phenyl-1H-indole-3-carboxamide structure, whether or not further substituted in the indole ring or the phenyl ring to any extent;</li> </ol>	6/11/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Louisiana  2015 HB 72 (Continued) (Page 2 of 2)	Adds the following substances to Schedule I: (11) Butaldehydeamidoindoles: Any compound containing a N-(1-oxobutan-2yl)-1H-indole-3-carboxamide structure, with or without substitution in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further substituted on the butaldehyde group to any extent; (12) Phenylpropionaldehydeamidoindoles: Any compound containing a N-(1-oxo-3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without substitution in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further substituted on the phenylpropionaldehyde group to any extent; (13) Cumylindolecarboxamides: Any compound containing a N-(2-phenylpropane-2-yl)-1H-indole-3-carboxamide structure, with or without substitution in the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, morpholinoethyl, alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further substituted on the phenyl group to any extent; (14) 1-(5-fluoropentyl)N-naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-carboxamide; (15) N-fenchyl-1-[2-(morpholin-4-yl)ethyl]-7-methoxyindole-3-carboxamide; (16) naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone; (17) naphthalen-1-yl(9-(5-fluoropentyl)-9H-carbazol-3-yl)methanone; (18) 1-methoxy-3,3-dimethyl-1-oxobutanyl-2yl-(1-cyclohexylmethyl)-1H-indazole-3-carboxylate.	6/11/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Louisiana 2015 HB 117	As part of a bill providing for a proposition election regarding the legalization of marijuana, removes marijuana from the controlled substance schedules.	4/13/2015 – read and referred to Committee on Administration of Criminal Justice.
Louisiana 2015 HB 174	Adds the following substances to Schedule IV: (1) Tramadol (2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol; (2) Suvorexant.  Repeals the Schedule III classification for hydrocodone combination products to make state law consistent with federal scheduling classifications.	6/23/2015 – enacted (2015 Laws Chapter 189); effective 6/23/2015.
Maine 2015 SP 259	Adds Acetylfentanyl to the list of Schedule W drugs.	6/2/2015 – passed by House.
Maryland 2015 HB 1057	Adds “synthetic cannabinoid” to the list of substances in Schedule I. “Synthetic cannabinoid” means a “synthetic chemical compound that is a cannabinoid receptor agonist and that mimics the pharmacological effect of a naturally occurring cannabinoid or a controlled dangerous substance listed in schedule I or schedule II.” It includes “a substance or an analog of a substance that is designed, generated, or recombined to create a new structure using a three-component pharmacophore model and that contains one or more pharmacophores or components of a controlled dangerous substance listed in schedule I or schedule II.” It does not include any drug that has been approved by the federal Food and Drug Administration.	3/20/2015 – first reading in Senate; referred to Committee on Judiciary Proceedings.
Massachusetts 2015 HB 1155	Adds the following substances to Class B: (1) , 2-(4-iodo-2 ,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5); (2) 2-(4-chloro-2 ,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82), (3) 2-(4-bromo-2 ,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36).	3/10/2015 – referred to Joint Committee on Judiciary.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Massachusetts  2015 HB 1478	<p>Adds the following substances to Class C:</p> <p>Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any Cannabimimetic Agents that meet the criteria of any one or more of paragraphs (a) through (e) and any substance within the structural classes identified below that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays:</p> <ol style="list-style-type: none"> <li>(1) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent;</li> <li>(2) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;</li> <li>(3) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the naphthoyl ring to any extent;</li> <li>(4) 1-(1-naphthylmethyl)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent;</li> <li>(5) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.</li> </ol>	3/10/2015 – referred to Joint Committee on Judiciary.
Massachusetts  2015 HB 1561	Among many other provisions, removes marijuana from Class D.	3/10/2015 – referred to Joint Committee on Judiciary.
Massachusetts  2015 HB 1791	Adds oxycodone as a Class A substance.	6/3/2015 – hearing scheduled 6/8/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Massachusetts 2015 SB 790	Adds Salvia Divinorum and Salvinorin A as Class C substances.	4/15/2015 – referred to Joint Committee on Judiciary.
Massachusetts 2015 SB 839	Places heroin in a newly created Class X, and adds the following penalty provision:  “Any person who knowingly or intentionally manufactures, distributes, dispenses, or possesses with intent to manufacture, distribute or dispense a controlled substance in Class X of section thirty-one shall be punished by imprisonment in the state prison for not less than one hundred years or in a jail or house of correction for not more than one hundred years and by a fine of not less than one thousand nor more than ten thousand dollars, or by both such fine and imprisonment.”	6/3/2015 – hearing scheduled for 6/9/2015.
Massachusetts 2015 SB 1035	Adds the following substances to Class:  (1) salvinorin A; (2) salvinorin B; (3) 2-methoxymethyl salvinorin B.	4/15/2015 – referred to Joint Committee on Mental Health and Substance Abuse.
Massachusetts 2015 SB 1036	Amends Class B schedule to include the following provision:  Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances including salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomer is possible within the specific chemical designations:  (1) Phenyl-2-propanone (p2p) (2) Phenylcyclohexylamine (PCH) (3) Piperidinocyclohexanecarbonitrile (PCC) (4) 3, 4 methylenedioxy methamphetamine (MDMA).	4/15/2015 – referred to Joint Committee on Mental Health and Substance Abuse.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Massachusetts  2015 SB 1037	Amends Class B schedule to include the following provision:  Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: Coca leaves, and the salts, optical and geometric isomers and salts of isomers, excluding coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed; of cocaine, ecgonine, pseudococaine, allococaine and pseudoallococaine, their derivatives, their salts, isomers and salts of their isomers; or any compound, mixture, or preparation which contains any quantity of any of the substances referred to in this paragraph.	4/15/2015 – referred to Joint Committee on Mental Health and Substance Abuse.
Massachusetts  2015 SB 1038	Adds the following substances to Class A: (1) 4- bromo-2,5- dimethoxyphenylethylamine (2C-B); (2) 2,5- dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); (3) N-benzylpiperazine (BZP).	4/15/2015 – referred to Joint Committee on Mental Health and Substance Abuse.
Massachusetts  2015 SB 1049	Adds acetyl fentanyl and alphaprodine as Class B substances. Removes acetorphine from Class B.	4/15/2015 – referred to Joint Committee on Mental Health and Substance Abuse.
Michigan	No pending proposed legislation.	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
Minnesota  2015 SF 878 (Page 1 of 2)	Adds the following substances to Schedule I: (1) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe); (2) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe); (3) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) . ; (4) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (5) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2); (6) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP); (7) 4-methyl-N-ethylcathinone (4-MEC); (8) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); (9) 2-(methylamino)-1-phenylpentan-1-one (pentedrone); (10) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone); (11) 4-fluoro-N-methylcathinone (4-FMC); (12) 3,4-methylenedioxy-N-ethylcathinone (ethylone); (13) alpha-pyrrolidinobutiophenone (&#945;-PBP); (14) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB); (15) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); (16) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide(AB-CHMINACA); (17) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5-fluoro-AMB); (18) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201); (19) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA); (20) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12); (21) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA); (22) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; (23) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; (24) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate.	5/22/2015 – enacted (2015 Laws Chapter 65); effective 7/1/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Minnesota</p> <p>2015 SF 878 (Continued) (Page 2 of 2)</p>	<p>Adds the following substances to Schedule II:</p> <ul style="list-style-type: none"> <li>(1) naloxegol;</li> <li>(2) 4-Anilino-N-phenethyl-4-piperidine (ANPP);</li> </ul> <p>Adds the following substances to Schedule III:</p> <ul style="list-style-type: none"> <li>(1) Perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-Dihydropyridin-3-yl) benzonitrile];</li> <li>(2) methasterone (2 alpha-17 alpha-dimethyl-5 alpha-androstan-17beta-ol-3-one);</li> <li>(3) prostanazol (17 beta-hydroxy-5 alpha-androstano[3,2-C]pyrazole);</li> <li>(4) Chorionic gonadotropin.</li> </ul> <p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> <li>(1) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> <li>(2) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</li> </ul> <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol, its salts, optical and geometric isomers, and salts of these isomers (including tramadol);</li> <li>(2) Alfaxalone (5α-pregnan-3α-ol-11,20-dione);</li> <li>(3) fospropofol;</li> <li>(4) nordiazepam;</li> <li>(5) petrichloral;</li> <li>(6) Suvorexant;</li> <li>(7) lorcaserin.</li> </ul> <p>Adds ezogabine to Schedule V.</p>	<p>5/22/2015 – enacted (2015 Laws Chapter 65); effective 7/1/2015.</p>
<p>Minnesota</p> <p>2015 HF 849</p>	<p>Same controlled substance provisions as 2015 SF 878.</p>	<p>4/25/2015 – substituted by 2015 SF 878.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Minnesota 2015 HF 1376	Same controlled substance provisions as 2015 SF 878.	4/30/2015 – substituted by 2015 SF 1219.
Minnesota 2015 SF 1219	Same controlled substance provisions as 2015 SF 878.	4/30/2015 – second reading in House.
Minnesota 2015 SF 2216	Removes marijuana and tetrahydrocannabinols from Schedule I and provides that the Minnesota Board of Pharmacy will recommend the appropriate schedule by January 1, 2016.	5/16/2015 – introduced and referred to Committee on Health, Human Services and Housing.
Mississippi 2015 HB 241	Adds “derivatives of synthetic cannabinoids” to Schedule I.	2/3/2015 – died in committee.
Mississippi 2015 HB 562	Removes “industrial hemp as regulated in Sections 1 through 3 of House Bill No. , 2015 Regular Session” from the definition of Tetrahydrocannabinols.	2/3/2015 – died in committee.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

© 2015 Research is current as of June 30, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or [jwoodruff@namsdl.org](mailto:jwoodruff@namsdl.org) with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>Mississippi</p> <p>2015 HB 1332</p>	<p>Adds the following substances to Schedule I:</p> <p>Synthetic cathinones unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cothinone found in any of the following compounds, whether or not substituted to any extent, or any of those compounds which contain any synthetic cothinone salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of isomers is possible:</p> <ul style="list-style-type: none"> <li>(1) 4-methyl-N-ethylcathinone ("4-MEC");</li> <li>(2) 4-methyl-alpha-pyrrolidinopropiophenone ("4-MePPP");</li> <li>(3) alpha-pyrrolidinopentiophenone ("a-PVP");</li> <li>(4) 1-(1,3-vebziduijik-5-yl)-2-(methylamino)butan-1-one ("butylone);</li> <li>(5) 2-(methylamino)-1-phenylpentan-1-one ("pentedrone");</li> <li>(6) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one ("pentylone");</li> <li>(7) 4-fluoro-N-methylcathinone ("4-FMC");</li> <li>(8) 3-fluoro-N-methylcathinone ("3-FMC");</li> <li>(9) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one("naphyrone");</li> <li>(10) alpha-pyrrolidinobutiophenone("a-PBP").</li> </ul> <p>Adds Perampanel to Schedule III.</p> <p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> <li>(1) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> <li>(2) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</li> </ul> <p>Adds Alfaxalone to Schedule IV.</p>	<p>2/3/2015 – died in committee.</p>
<p>Mississippi</p> <p>2015 SB 2118</p>	<p>Similar to 2015 HB 1332.</p>	<p>3/30/2015 – died in conference.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Mississippi 2015 SB 2318	Moves marijuana, hashish and Tetrahydrocannabinols from Schedule I to Schedule II.	2/3/2015 – died in committee.
Missouri 2015 HB 701	Exempts industrial hemp from definition of marijuana in Schedule I.	2/10/2015 – referred to Emerging Issues Committee.
Missouri 2015 HB 830	Exempts industrial hemp from definition of marijuana in Schedule I.	5/4/2015 – Senate committee substitute reported do pass.
Missouri 2015 HB 930	Among many other provisions, moves marijuana from Schedule I to Schedule II.	4/8/2015 – public hearing completed.
Missouri 2015 HB 1170	Adds provision that “beginning January 1, 2017, the director of the department of health and senior services shall notify the revisor of statutes of any controlled substances that are added or removed from the five schedules of controlled substances established by the federal Controlled Substances Act under 21 U.S.C. section 801, et seq. The revisor shall change the statutory schedule of controlled substances listed in this section to include such additions or deletions.”	4/13/2015 – House committee voted do pass.
Missouri 2015 SB 255	Among many other provisions, the bill exempts industrial hemp, which is defined as cannabis sativa L. containing no greater than 3/10 of one percent THC, from the definition of marijuana and the list of controlled substances.	4/1/2015 – Senate committee substitute voted do pass.
Montana  Administrative Register Notice 24-174-66 (Page 1 of 2)	Changes are made to make Montana schedules consistent with federal schedules.  Naloxegol is removed from Schedule II.  The following substances are added to Schedule III: (1) methasterone; (2) perampanel; (3) prostanazol.	5/14/2015 – notice of public hearing on regulations scheduled for 6/23/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

© 2015 Research is current as of June 30, 2015. In order to ensure that the information contained herein is as current as possible, research is conducted using nationwide legal database software and individual state legislative websites. Please contact Jon Woodruff at (703) 836-6100, ext. 100 or jwoodruff@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 420 Park Street, Charlottesville, VA 22902.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Montana</p> <p>Administrative Register Notice 24-174-66 (Continued) (Page 2 of 2)</p>	<p>Removes hydrocodone combination products from Schedule III.</p> <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) tramadol;</li> <li>(2) alfaxalone;</li> <li>(3) suvorexant;</li> <li>(4) lorcaserin.</li> </ul> <p>Adds ezogabine to Schedule V.</p>	<p>5/14/2015 – notice of public hearing on regulations scheduled for 6/23/2015.</p>
<p>Nebraska</p> <p>2015 LB 189</p>	<p>Adds marijuana concentrate to Schedule I. Removes hashish, concentrated cannabis, and Tetrahydrocannabinols from Schedule I.</p> <p>Changes the definition of Synthetic Tetrahydrocannabinols in Schedule I to: “Any equivalent of the substances naturally contained in a plant of the genus cannabis or derivatives and their isomers with similar chemical structure and pharmacological activity. Synthetic tetrahydrocannabinols includes the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers. Synthetic tetrahydrocannabinols does not include dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the federal Food and Drug Administration.”</p>	<p>2/20/2015 – Judiciary Committee amendment filed.</p>
<p>Nebraska</p> <p>2015 LB 326</p>	<p>Similar to 2015 LB 390.</p>	<p>5/29/2015 – indefinitely postponed.</p>
<p>Nebraska</p> <p>2015 LB 390 (Page 1 of 2)</p>	<p>Revises descriptions of synthetically produced cannabinoids in Schedule I.</p> <p>Adds the following substances to Schedule II:</p> <ul style="list-style-type: none"> <li>(1) Lisdexamfetamine;</li> <li>(2) Immediate precursor to fentanyl; 4-anilino-N-phenethyl-4-piperidine (ANNPP).</li> </ul> <p>Adds the following substances to Schedule III:</p> <ul style="list-style-type: none"> <li>(1) Embutramide;</li> <li>(2) Perampanel.</li> </ul>	<p>5/27/2015 – enacted; effective 5/27/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Nebraska</p> <p>2015 LB 390 (Continued) (Page 2 of 2)</p>	<p>Makes numerous revisions to the listing of anabolic steroids in Schedule III.</p> <p>Removes the following combination products from Schedule III:</p> <ul style="list-style-type: none"> <li>(1) Not more than three hundred milligrams of dihydrocodeinone which is also known as hydrocodone per one hundred milliliters or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> <li>(2) Not more than three hundred milligrams of dihydrocodeinone which is also known as hydrocodone per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.</li> </ul> <p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) Zopiclone;</li> <li>(2) Fospropofol;</li> <li>(3) Alfaxalone;</li> <li>(4) Suvorexant;</li> <li>(5) Carisoprodol;</li> <li>(6) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol, its salts, optical and geometric isomers and salts of these isomers to include: Tramadol;</li> <li>(7) Pentazocine;</li> <li>(8) Butorphanol;</li> <li>(9) Lorcaserin.</li> </ul>	<p>5/27/2015 – enacted; effective 5/27/2015.</p>
<p>Nevada</p> <p>2015 SB 234</p>	<p>Requires the state Board of Pharmacy to designate, by extraordinary regulation, salvia divinorum and certain substances commonly known as synthetic marijuana in the list of schedule I controlled substances.</p>	<p>4/11/2015 – no further action allowed.</p>
<p>Nevada</p> <p>LCB File No. R133-14</p>	<p>Adds Tramadol to Schedule IV.</p>	<p>3/3/2015 – regulation adopted; effective 6/26/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Nevada</p> <p>LCB File No. R142-14</p>	<p>Regulation proposed to add the following substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (some trade or other names: AB-CHMINACA);</li> <li>(2) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (some trade or other names: THJ-2201; 5-fluoro THJ 018; AM2201 indazole analog; fluoropentyl JWH-018 indazole);</li> <li>(3) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (some trade or other names: AB-PINACA);</li> <li>(4) 1-pentyl-N-(tricyclo[3.3.1.1 3,7]dec-1-yl)-1H-indole-3-carboxamide (some trade or other names: APICA; JWH-018 adamantyl carboxamide; 2NE1; SDB-001);</li> <li>(5) Salvinorin A (some trade or other names: Divinorin A; Methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-Dioxododecahydro -2H-benzo[f]isochromene-7-carboxylate);</li> <li>(6) Dimethylone (some trade or other names: 3,4-methylenedioxy-N,Ndimethylcathinone; N,N-dimethyl MDCATH; N,N-dimethyl-3,4-methylenedioxyamphetaminone; N,N-dimethyl-β-keto-3,4-methylenedioxyamphetamine; 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one; bk-MDDMA);</li> <li>(7) Ethylone (some trade or other names: N-ethyl-3,4-methylenedioxyamphetaminone; 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one; MDEC; bk-MDEA).</li> </ol>	<p>4/29/2015 – updated agency draft posted.</p>
<p>Nevada</p> <p>LCB File No. R004-15</p>	<p>Adds Suvorexant to Schedule IV.</p>	<p>5/4/2015 – LCB proposed draft posted.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>New Hampshire</p> <p>2015 SB 106 (Page 1 of 9)</p>	<p>New Hampshire does not publish a state list of controlled substances, instead relying on the federal schedules. This legislation makes it illegal to sell or distribute “any substance containing a synthetic drug,” noting that the drugs classified as “synthetic drugs” are not all on the federal controlled substance schedules.</p> <p>The definition of “synthetic drug” is:</p> <ul style="list-style-type: none"> <li>(1) Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with a substituent at the 5-position of the phenolic ring: whether or not substituted on the cyclohexyl ring to any extent;</li> <li>(2) Any compound containing a 1-(1-naphthylmethyl)indene ring system with a substituent at the 3-position of the indene ring system: whether or not further substituted on the indene ring to any extent, and whether or not substituted on the naphthyl ring to any extent;</li> <li>(3) Any compound containing an indole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the indole ring system, with a linkage connecting the ring system to the substituent: <ul style="list-style-type: none"> <li>a. Where the linkage connecting the indole ring system to the substituent at its 3-position is any of the following: (A) Alkyl, (B) Carbonyl, (C) Ester, (D) Thione, (E) Thioester, (F) Amino, (G) Alkylamino, (H) Amido, (I) Alkylamido.</li> <li>b. Where the substituent at the 3-position of the indole ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl, (B) Quinoliny, (C) Adamantyl, (D) Phenyl, (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), (F) Biphenyl, (G) Alkylamido (limited to ethylamido, propylamido, butylamido, or pentylamido), (H) Benzyl, (I) Carboxylic acid, (J) Ester, (K) Ether, (L) Phenylpropylamido, (M) Phenylpropylamino.</li> </ul> </li> </ul>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 2 of 9)</p>	<p>c. Whether or not the substituent at the 3-position of the indole ring system, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the indole ring system to any extent.</p> <p>(4) Any compound containing an indazole ring system with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the indazole ring system, with a linkage connecting the ring system to the substituent:</p> <p>a. Where the linkage connecting the indazole ring system to the substituent at its 3-position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester. (F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3-position of the indazole ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl. (E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido.(M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3-position of the indazole ring system, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the indazole ring system to any extent.</p>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 3 of 9)</p>	<p>(5) Any compound containing a pyrrole ring with a substituent on the nitrogen atom and bearing an additional substituent at the 3-position of the pyrrole ring, with a linkage connecting the ring to the substituent:</p> <p>a. Where the linkage connecting the pyrrole ring to the substituent at its 3-position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3-position of the pyrrole ring is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinolinylnyl.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3-position of the pyrrole ring, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the pyrrole ring to any extent.</p> <p>(6) Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:</p> <p>a. Where the linkage connecting the pyrazole ring to the substituent at its 3-position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3-position of the pyrazole ring is, disregarding the linkage, any of the following groups:</p>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 4 of 9)</p>	<p>(A) Naphthyl.(B) Quinoliny.(C) Adamantyl.(D) Phenyl.(E) Cyclopentyl, or cyclohexyl.(F) Cycloalkyl (limited to cyclopropyl, cyclobutyl, or biphenyl).(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3-position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the pyrazole ring to any extent.</p> <p>(7) Any compound containing a pyrazole ring with a substituent at the 1-position nitrogen atom and bearing an additional substituent at the 3-position of the pyrazole ring with a linkage connecting the ring to the substituent:</p> <p>a. Where the linkage connecting the pyrazole ring to the substituent at its 3 position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p>b. Where the substituent at the 3 position of the pyrazole ring is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinoliny.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido.(M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 3 position of the pyrazole ring, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the pyrazole ring to any extent.</p>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 5 of 9)</p>	<p>(8) Any compound containing a naphthalene ring system with a substituent on the 1 position carbon atom and bearing an additional substituent at the 4 position of the naphthalene ring system, with a linkage connecting the ring system to the substituent:</p> <p style="padding-left: 40px;">a. Where the linkage connecting the naphthalene ring system to the substituent at its 4 position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p> <p style="padding-left: 40px;">b. Where the substituent at the 4 position of the naphthalene ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinoliny.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butylamido, or pentylamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p style="padding-left: 40px;">c. Whether or not the substituent at the 4 position of the naphthalene ring system, disregarding the linkage, is further substituted to any extent.</p> <p style="padding-left: 40px;">d. Whether or not further substituted on the naphthalene ring system to any extent.</p> <p>(9) Any compound containing a carbazole ring system with a substituent on the nitrogen atom and bearing an additional substituent at the 1, 2, or 3 position of the carbazole ring system, with a linkage connecting the ring system to the substituent:</p> <p style="padding-left: 40px;">a. Where the linkage connecting the carbazole ring system to the substituent at its 1, 2, or 3 position is any of the following: (A) Alkyl.(B) Carbonyl.(C) Ester.(D) Thione.(E) Thioester.(F) Amino.(G) Alkylamino.(H) Amido.(I) Alkylamido.</p>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 6 of 9)</p>	<p>b. Where the substituent at the 1, 2, or 3 position of the carbazole ring system is, disregarding the linkage, any of the following groups: (A) Naphthyl.(B) Quinoliny.(C) Adamantyl.(D) Phenyl.(E) Cycloalkyl (limited to cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).(F) Biphenyl.(G) Alkylamido (limited to ethylamido, propylamido, butanamido, or pentanamido).(H) Benzyl.(I) Carboxylic acid.(J) Ester.(K) Ether.(L) Phenylpropylamido. (M) Phenylpropylamino.</p> <p>c. Whether or not the substituent at the 1, 2, or 3 position of the carbazole ring system, disregarding the linkage, is further substituted to any extent.</p> <p>d. Whether or not further substituted on the carbazole ring system to any extent.</p> <p>(10) Any substance which includes, but is not limited to the following: (1) QUCHIC/BB-22; (2) STS-135; (3) APICA/SDB-001; (4) ADBICA; (5) ADB-FUBINACA; (6) AB-001; (7) SDB-006; (8) EG-018; (9) CB-13; (10) 5-chloro-UR-144; (11) FUB-PB-22.</p> <p>(11) Any synthetic cathinone, which shall be defined as any of the following chemical structures, their salts, isomers and salts of isomers, whenever the existence of these is possible within the specific chemical designation, including any compound structurally derived from 2-aminopropanal by substitution at the 1-position with a monocyclic or fused polycyclic ring system, including compounds further modified by:</p> <p>a. Substitution on the ring system to any extent (including, but not limited to alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents), whether or not further substituted in the ring system by other substituents; and/or</p>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>New Hampshire</p> <p>2015 SB 106 (Continued) (Page 7 of 9)</p>	<p>b. Substitution at the 3-position with a saturated or unsaturated hydrocarbon substituent; and/or</p> <p>c. Mono- or di- substitution at the 2-amino nitrogen atom with saturated or unsaturated hydrocarbon groups, or inclusion of the 2-amino nitrogen atom in a cyclic structure, whether or not that cyclic structure contains any further substitutions;</p> <p>d. Includes, but is not limited to: 3,4-dimethylmethcathinone (3,4-DMMC); Beta-ketoethylbenzodioxolylbutanamine (eutylone); 3,4-methylenedioxy-N-ethylcathinone (ethylone).</p> <p>e. 4-methoxymethcathinone (methedrone) This term shall not include substances that are otherwise scheduled under the Controlled Substances Act: (e.g. cathinone, methcathinone, methylone, mephedrone, MDPV, diethylpropion, pyrovalerone), are FDA-approved pharmaceutical products (i.e. bupropion) or are FDA-approved research products.</p> <p>(12) (l) Any synthetic psychoactive compound or substance which shall be defined as substances and their salts, isomers, and salts of isomers, wherever the existence of these is possible, within the following specific chemical designation:</p> <p>a. 2,5-dimethoxy-4-methyl-N-(2-methoxybenzyl) phenethylamine (also known as 25D-NBOMe);</p> <p>b. 2,5-dimethoxy-4-ethyl-N-(2-methoxybenzyl) phenethylamine (also known as 25E-NBOMe);</p> <p>c. 2,5-dimethoxy-4-nitro-N-(2-methoxybenzyl) phenethylamine (also known as 25N-NBOMe);</p> <p>d. 2,5-dimethoxy-4-n-propyl-N-(2-methoxybenzyl) phenethylamine (also known as 25P-NBOMe);</p> <p>e. 2,5-dimethoxy-4-ethylthio-N-(2-methoxybenzyl) phenethylamine (also known as 25T2-NBOMe);</p>	<p>6/24/2015 – enrolled.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
New Hampshire  2015 SB 106 (Continued) (Page 8 of 9)	<ul style="list-style-type: none"> <li>f. 2,5-dimethoxy-4-sec-propylthio-N-(2-methoxybenzyl) phenethylamine (also known as 25T4-NBOMe);</li> <li>g. 2,5-dimethoxy-4-n-propylthio-N-(2-methoxybenzyl) phenethylamine (also known as 25T7-NBOMe);</li> <li>h. N-(2-methoxybenzyl)-3,4-dimethoxyamphetamine (also known as 34-DMA NBOMe);</li> <li>i. 1-(1-Benzofuran-2-yl)propan-2-amine (also known as 2-APB);</li> <li>j. 5-(2-aminopropyl)-2,3-dihydrobenzofuran (also known as 5-APDB);</li> <li>k. 2-(2-ethylaminopropyl)benzofuran (also known as 2-EAPB);</li> <li>l. 1-(Benzofuran-5-yl)-N-methylpropan-2-amine (also known as 5-MAPB);</li> <li>m. 3,4-dichloromethylphenidate;</li> <li>n. 5,6-methylenedioxy-2-aminoindan (also known as 5,6-MDAI);</li> <li>o. 4-hydroxy-diethyltryptamine (also known as 4-hydroxy-DET);</li> <li>p. 4-methoxyphencyclidine (also known as 4-methoxy-PCP or methoxydine);</li> <li>q. 3,4-dichloro-N-([1-(dimethylamino)cyclohexyl]methyl)benzamide (also known as AH-7921);</li> <li>r. Benocyclidine (also known as BTCP);</li> <li>s. Methoxetamine (also known as MXE);</li> <li>t. 3-Methyl-6-[3-trifluoromethyl]phenyl]-1,2,4-triazolo[4,3-b]pyridazine (also known as CL218872);</li> <li>u. 1-(1,2-diphenylethyl)piperidine (also known as diphenidine);</li> <li>v. 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (also known as MT-45);</li> <li>w. (3-diethylamino-2,2-dimethylpropyl)-4-nitrobenzoate (also known as nitrocaine or nitracaine);</li> <li>x. (E)-4-chloro-N-1(phenylethyl)piperidin-2-ylidene)sulfonamide (also known as W-15);</li> </ul>	6/24/2015 – enrolled.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
New Hampshire  2015 SB 106 (Continued) (Page 9 of 9)	<ul style="list-style-type: none"> <li>y. (E)-4-chloro-N-(1-(4-nitrophenylethyl)piperidin-2-ylidene)sulfonamide (also known as W-18);</li> <li>z. 4-fluoroamphetamine;</li> <li>aa. 1-(thiophen-2-yl)-2-methylaminopropane (also known as methiopropamine).</li> </ul> <p>(13) This definition shall not include:</p> <ul style="list-style-type: none"> <li>a. Endocannabinoids that are naturally found in the human body</li> <li>b. Delta-9 Tetrahydrocannabinol (THC) or other marijuana-derived cannabinoids, in the form of marinol, dronabinol, or another generic pharmaceutical equivalent, provided the medication has been issued as the result of a valid prescription; or</li> <li>c. (3) Any other drugs that have cannabinoid receptor activity that are currently approved by the United States Food and Drug Administration for medical use; or marijuana and extracts of marijuana authorized for therapeutic use pursuant to RSA 126-X.</li> </ul>	6/24/2015 – enrolled.
New Jersey	No pending proposed legislation.	
New Mexico  2015 HB 160	Provides that term “controlled substance” does not include “industrial hemp or marijuana for purpose of or conduct pursuant to and in compliance with the Cannabis Revenue and Freedom Act.”	1/22/2015 – referred to committees.
New Mexico  2015 HB 294	Moves the following combination products to Schedule II: (1) not more than three hundred milligrams of dihydrocodeinone, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; or (2) not more than three hundred milligrams of dihydrocodeinone, or any of its salts, per one hundred milliliters or not more than fifteen milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.	2/18/2015 – “do pass” committee report adopted.
New Mexico  2015 SB 94	Among other provisions, provides that “the enumeration of marijuana, tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinol as Schedule I controlled substances does not apply to: (1) research and development of industrial hemp by qualified entities pursuant to rules adopted by the New Mexico department of agriculture.”	3/6/2015 – passed House.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
New Mexico  16.19.20 NMAC	Deletes the following hydrocodone products from Schedule III: (1) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (2) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts; (3) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.	4/16/2015 – notice of proposed rules.
New York  2015 AB 627	Adds the following substances to Schedule I: (1) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine, also known as 25I-NBOMe; 2C-I-NBOMe; 25I; or Cimbi-5. (2) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine, also known as 25 CNBOMe; 2C-C-NBOMe; 25C; or Cimbi-82. (3) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, also known as, 25 BNBOMe; 2C-B-NBOMe; Cimbi-36.	6/16/2015 – passed Senate.
New York  2015 AB 1910 (Page 1 of 2)	Adds the following substances to Schedule I:  (g)(1) Cannabimimetic agents. Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation that is not approved by the federal food and drug administration (FDA) which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.  (2) As used in this subdivision, the term "cannabimimetic agents" means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:	6/17/2015 – passed Assembly and delivered to Senate.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>New York</p> <p>2015 AB 1910 (Continued) (Page 2 of 2)</p>	<p>(1) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.</p> <p>(2) 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.</p> <p>(3) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.</p> <p>(4) 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.</p> <p>(5) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.</p> <p>(3) Such term includes:</p> <p>(1) 5-(1,1-dimethylheptyl)- phenol (CP-47,497);</p> <p>(2) 5-(1,1-dimethyloctyl)-2-phenol (cannabicyclohexanol or CP-47,497 C8-homolog);</p> <p>(3) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);</p> <p>(4) 1-butyl-3-(1-naphthoyl)indole (JWH-073);</p> <p>(5) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);</p> <p>(6) 1-3-(1-naphthoyl)indole (JWH-200);</p> <p>(7) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);</p> <p>(8) 1-pentyl-3 indole (JWH-081);</p> <p>(9) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);</p> <p>(10) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);</p> <p>(11) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);</p> <p>(12) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);</p> <p>(13) 1-pentyl-3 indole (SR-19 and RCS-4);</p> <p>(14) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8); and</p> <p>(15) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).</p>	<p>6/17/2015 – passed Assembly and delivered to Senate.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
New York 2015 AB 3089	Among many other provisions, removes marijuana from Schedule I.	3/2/2015 – amend and recommit to Committee on Assembly Codes.
New York 2015 AB 4059	Adds provision to New York law that the state controlled substance schedules include any substances “designated pursuant to the federal Analog Act (21 U.S.C. § 813).”	1/29/2015 – introduced and referred to Committee on Assembly Health.
New York 2015 AB 4579	Adds the following substances to Schedule I: (1) "Synthetic cannabinoid" means any material, compound, mixture or preparation containing any quantity of: a. CP 47,497 and homologues: 2-5-(2-methyloctan-2-yl)phenol; b. HU-210; c. HU-211: (dexanabinol, (6aS, 10aS)-9-(hydroxymethyl) -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo chromen-1-ol); d. JWH-o18: 1-Pentyl-3-(1-naphthoyl)indole; or e. (e) JWH-o73: 1-Butyl-3-(1-naphthoyl)indole. (2) CP 47,497 and homologues: 2-5-(2-methyloctan-2-yl)phenol; (3) HU-210; (4) HU-211: (dexanabinol, (6aS, 10aS)-9-(hydroxymethyl) -6,6-dimethyl -3-(2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo chromen-1-ol); (5) JWH-o18: 1-Pentyl-3-(1-naphthoyl)indole; (6) JWH-o73: 1-Butyl-3-(1-naphthoyl)indole.	2/3/2015 – introduced and referred to Committee on Assembly Health.
New York 2015 AB 7336	Adds Alpha-PVP, its salts, optical isomers and salts of optical isomers to Schedule I.	5/6/2015 – introduced and referred to Committee on Assembly Health.
New York 2015 SB 738	Substituted by 2015 AB 627.	6/16/2015 – substituted by 2015 AB 627.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
New York 2015 SB 1640	Companion bill to 2015 AB 4059	6/9/2015 – passed Senate.
New York 2015 SB 1747	Companion bill to 2015 AB 3089	1/14/2015 – introduced and referred to Committee on Senate Health.
New York 2015 SB 2836 (Page 1 of 3)	Adds the following substances to Schedule I: (1) “Synthetic cannabinoid” means any material, compound, mixture or preparation containing any quantity of: <ul style="list-style-type: none"> <li>a. Tetrahydrocannabinols, naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylideneindenes, phenylacetylindoles, cyclohexylphenols, benzoylindoles, or adamantoylindoles, as defined in section thirty-three hundred six of this title;</li> <li>b. (6aR, 10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzocchromen-1-ol (HU-210);</li> <li>c. (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)- 6a,7,10,10a-tetrahydrobenzocchromen-1-ol (Dexanabinol or HU-211); or</li> <li>d. 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo1,2,3-de-1, 4-benzoxazin-6-y1-1-naphthalenylmethanone (WIN 55,212-2).</li> </ul>	6/17/2015 – passed Senate.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
New York  2015 SB 2836 (Continued) (Page 2 of 3)	Adds the following substances to Schedule I: (2) Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (3) Naphthylmethylinindoles. Any compound containing a H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (4) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (5) Naphthylideneindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent; (6) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.	<a href="#">6/17/2015 – passed Senate.</a>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>New York</p> <p>2015 SB 2836 (Continued) (Page 3 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <p>(7) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent;</p> <p>(8) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;</p> <p>(9) Adamantoylindoles. Any compound containing a 3-(1-adamantoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperindinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the adamantyl ring system to any extent;</p> <p>(10) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzocchromen-1-ol (HU-210);</p> <p>(11) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) -6a,7,10,10a-tetrahydrobenzocchromen-1-ol (Dexanabinol or HU-211);</p> <p>(12) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo1,2,3-de-1, 4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).</p>	<p>6/17/2015 – passed Senate.</p>
<p>New York</p> <p>2015 SB 4544</p>	<p>Adds 120 milligrams or more of pseudoephedrine to Schedule II.</p>	<p>4/27/2015 – amended and recommitted to Committee on Assembly Codes.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>New York</p> <p>2015 SB 4712</p>	<p>Adds the following definition to the controlled substance law.</p> <p>“Synthetic cannabinoid” means any chemical compound that is chemically synthesized and: (a) has been demonstrated to have a binding activity at one or more cannabinoid receptors; or (b) is a chemical isomer, salt or salt of an isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors.</p> <p>“Synthetic cannabinoid” does not include any products that have been approved for medical use by the United States Food and Drug Administration.</p> <p>“Synthetic cannabinoid analog” means any chemical that is substantially similar in chemical structure to a chemical compound that has been determined to have binding activity at one or more cannabinoid receptors. It does not include any products that have been approved for medical use by the United States Food and Drug Administration.</p>	<p>4/10/2015 – introduced and referred to Committee on Senate Health.</p>
<p>New York</p> <p>2015 SB 4720 (Page 1 of 2)</p>	<p>Adds the following definitions to the controlled substances law:</p> <p>"Synthetic cannabinoid" means any chemical compound that is chemically synthesized and: (a) has been demonstrated to have a binding activity at one or more cannabinoid receptors; or (b) is a chemical isomer, salt or salt of an isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors; or (c) has been designated in regulation by the commissioner as being a synthetic cannabinoid or synthetic cannabinoid analog.</p> <p>"Synthetic cannabinoid" does not include any product that has been approved for medical use by the United States Food and Drug Administration.</p>	<p>4/10/2015 – introduced and referred to Committee on Senate Health.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>New York</p> <p>2015 SB 4720 (Continued) (Page 2 of 2)</p>	<p>Adds the following definitions to the controlled substances law:</p> <p>"Synthetic cannabinoid analog" means any chemical that is substantially similar in chemical structure to a chemical compound that has been determined to have binding activity at one or more cannabinoid receptors. It does not include any products that have been approved for medical use by the United States Food and Drug Administration.</p> <p>"Substituted cathinone" means any chemical compound that is chemically synthesized and: (a) is a compound listed in paragraph five, eight or nine of subdivision (f) of Schedule I of section thirty-three hundred six of this article, or (b) has been designated in regulation by the commissioner as having a chemical structure derivative of cathinone, or (c) any compound, other than bupropion, that is structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:(i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;(ii) by substitution at the three-position with an alkyl substituent;(iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.</p>	<p>4/10/2015 – introduced and referred to Committee on Senate Health.</p>
<p>New York</p> <p>2015 SB 4743</p>	<p>Adds Alpha-PVP, its salts, optical isomers and salts of optical isomers to Schedule I.</p>	<p>6/15/2015 – passed Senate and referred to Assembly.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>North Carolina</p> <p>2015 HB 341</p>	<p>Adds the following substances to Schedule I:</p> <p>(1) Acetyl Fentanyl;</p> <p>(2) Methoxetamine (other names: MXE, 3-MeO-2-Oxo-PCE);</p> <p>(3) NBOMe Compounds. - Any material compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation unless specifically excepted or unless listed in another schedule:</p> <p>(1) 25B-NBOMe (2C-B-NBOMe) - 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(2) 25C-NBOMe (2C-C-NBOMe) - 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(3) 25D-NBOMe (2C-D-NBOMe) - 2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(4) 25E-NBOMe (2C-E-NBOMe) - 2-(4-Ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(5) 25G-NBOMe (2C-G-NBOMe) - 2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(6) 25H-NBOMe (2C-H-NBOMe) - 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(7) 25I-NBOMe (2C-I-NBOMe) - 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(8) 25N-NBOMe (2C-N-NBOMe) - 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(9) 25P-NBOMe (2C-P-NBOMe) - 2-(4-Propyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;</p> <p>(10) 25T2-NBOMe (2C-T2-NBOMe) - 2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-4-(methylthio)-benzeneethanamine;</p> <p>(11) 25T4-NBOMe (2C-T4-NBOMe) - 2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-4-[(1-methylethyl)thio]-benzeneethanamine;</p> <p>(12) 25T7-NBOMe (2C-T7-NBOMe) - 2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-4-(propylthio)-benzeneethanamine.</p>	<p>6/24/2015 – re-referred to Senate Committee on Judiciary.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>North Dakota</p> <p>2015 SB 2100 (Page 1 of 5)</p>	<p>Adds the following to Schedule I:</p> <p>Acetylfentanyl (also known as N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);</p> <p>Indole carboxaldehydes. Any compound structurally derived from 1H-indole-3-carboxaldehyde or 1H-2-carboxaldehyde substituted in both of the following ways: at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and, at the hydrogen of the carboxaldehyde by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group whether or not the compound is further modified to any extent in the following ways:</p> <ol style="list-style-type: none"> <li>(1) Substitution to the indole ring to any extent; or</li> <li>(2) Substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent; or</li> <li>(3) A nitrogen heterocyclic analog of the indole ring; or</li> <li>(4) A nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring.</li> <li>(5) Examples include: <ol style="list-style-type: none"> <li>a. 1-Pentyl-3-(1-naphthoyl)indole - Other names: JWH-018 and AM-678;</li> <li>b. 1-Butyl-3-(1-naphthoyl)indole - Other names: JWH-073;</li> <li>c. 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole - Other names: JWH-081;</li> <li>d. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole - Other names: JWH-200;</li> <li>e. 1-Propyl-2-methyl-3-(1-naphthoyl)indole - Other names: JWH-015;</li> <li>f. 1-Hexyl-3-(1-naphthoyl)indole - Other names: JWH-019;</li> <li>g. 1-Pentyl-3-(4-methyl-1-naphthoyl)indole - Other names: JWH-122;</li> </ol> </li> </ol>	<p>3/19/2015 – enacted (2015 Laws 2100); effective 3/19/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 2 of 5)</p>	<p>Adds the following to Schedule I:</p> <p>h. 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole - Other names: JWH-210;</p> <p>i. 1-Pentyl-3-(4-chloro-1-naphthoyl)indole - Other names: JWH-398;</p> <p>j. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole - Other names: AM-2201;</p> <p>k. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole - Other names: RCS-8;</p> <p>l. 1-Pentyl-3-(2-methoxyphenylacetyl)indole - Other names: JWH-250;</p> <p>m. 1-Pentyl-3-(2-methylphenylacetyl)indole - Other names: JWH-251;</p> <p>n. 1-Pentyl-3-(2-chlorophenylacetyl)indole - Other names: JWH-203;</p> <p>o. 1-Pentyl-3-(4-methoxybenzoyl)indole - Other names: RCS-4;</p> <p>p. (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) - Other names: AM-694;</p> <p>q. (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone - Other names: WIN 48,098 and Pravadoline;</p> <p>r. (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone -- Other names: UR-144;</p> <p>s. (1-(5-fluoropentyl)indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone - Other names: XLR-11;</p> <p>t. (1-(2-morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone - Other names: A-796,260;</p> <p>u. (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone -- Other names: THJ-2201;</p> <p>v. 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone -- Other names: THJ-018;</p>	<p>3/19/2015 – enacted (2015 Laws 2100); effective 3/19/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 3 of 5)</p>	<p>Adds the following to Schedule I:</p> <p>w. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone - Other names: FUBIMINA;</p> <p>x. 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl) indole - Other names: AM-1248;</p> <p>y. 1-Pentyl-3-(1-adamantoyl)indole - Other names: AB-001 and JWH-018 adamantyl analog.</p> <p>Indole carboxamides. Any compound structurally derived from 1H-indole-3-carboxamide or 1H-2-carboxamide substituted in both of the following ways: at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and, at the nitrogen of the carboxamide by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group whether or not the compound is further modified to any extent in the following ways:</p> <ol style="list-style-type: none"> <li>(1) Substitution to the indole ring to any extent; or</li> <li>(2) Substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent; or</li> <li>(3) A nitrogen heterocyclic analog of the indole ring; or</li> <li>(4) A nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring.</li> <li>(5) Examples include: <ol style="list-style-type: none"> <li>a. N-Adamantyl-1-pentyl-1H-indole-3-carboxamide - Other names: JWH-018 adamantyl carboxamide, APICA, SDB-001, and 2NE1;</li> <li>b. N-Adamantyl-1-fluoropentylindole-3-carboxamide - Other names: STS-135;</li> <li>c. N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide - Other names: AKB 48 and APINACA;</li> <li>d. N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide - Other names: NNEI and MN-24.</li> </ol> </li> </ol>	<p>3/19/2015 – enacted (2015 Laws 2100); effective 3/19/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 4 of 5)</p>	<p>Adds the following to Schedule I:</p> <ul style="list-style-type: none"> <li>e. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide - Other names: ADBICA;</li> <li>f. (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide - Other names: AB-PINACA;</li> <li>g. N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide - Other names: AB-FUBINACA;</li> <li>h. (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide - Other names: 5-Fluoro AB-PINACA;</li> <li>i. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide - Other names: ADB-PINACA;</li> <li>j. N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide - Other names: AB-CHMINACA;</li> <li>k. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide - Other names: ADB-FUBINACA;</li> <li>l. N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide - Other names: FUB-AKB48 and AKB48 N-(4-fluorobenzyl) analog;</li> <li>m. 1-(5-fluoropentyl)-N-(quinolin-8-yl)-1H-indazole-3-carboxamide - Other names: 5-fluoro-THJ;</li> <li>n. (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate - Other names: 5-fluoro AMB;</li> <li>o. methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate - Other names: FUB-AMB.</li> </ul>	<p>3/19/2015 – enacted (2015 Laws 2100); effective 3/19/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>North Dakota</p> <p>2015 SB 2100 (Continued) (Page 5 of 5)</p>	<p>Indole carboxylic acids. Any compound structurally derived from 1H-indole-3-carboxylic acid or 1H-2-carboxylic acid substituted in both of the following ways: at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and, at the hydroxyl group of the carboxylic acid by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group whether or not the compound is further modified to any extent in the following ways:</p> <ol style="list-style-type: none"> <li>(1) Substitution to the indole ring to any extent; or</li> <li>(2) Substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, propionaldehyde group to any extent; or</li> <li>(3) A nitrogen heterocyclic analog of the indole ring; or</li> <li>(4) A nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring.</li> <li>(5) Examples include: <ol style="list-style-type: none"> <li>a. 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester - Other names: BB-22 and QUCHIC;</li> <li>b. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate - Other names: FDU-PB-22;</li> <li>c. 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester - Other names: PB-22 and QUPIC;</li> <li>d. 1-(5-Fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester - Other names: 5-Fluoro PB-22 and 5F-PB-22;</li> <li>e. quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate - Other names: FUB-PB-22;</li> <li>f. [6] naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate - Other names: NM2201.</li> </ol> </li> </ol>	<p>3/19/2015 – enacted (2015 Laws 2100); effective 3/19/2015.</p>
<p>Ohio</p>	<p>No pending proposed legislation. Changes to the federal schedules of controlled substances automatically become part of the corresponding Ohio schedule.</p>	

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Oklahoma</p> <p>2015 HB 1616 (Page 1 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) Methoxetamine;</li> <li>(2) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA);</li> <li>(3) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA);</li> <li>(4) N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (NNE1);</li> <li>(5) 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide (5F-NNE1);</li> <li>(6) N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006);</li> <li>(7) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F-SDB-006).</li> </ol> <p>Indole Esters: Any compound containing a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole Esters include, but are not limited to:</p> <ol style="list-style-type: none"> <li>(1) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22);</li> <li>(2) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22);</li> <li>(3) quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22);</li> <li>(4) naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22);</li> <li>(5) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201)</li> </ol>	<p>5/12/2015 – enacted (2015 Laws Chapter 305); effective 8/29/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Oklahoma</p> <p>2015 HB 1616 (Continued) (Page 2 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <p>Adamantanoylindoles: Any compound containing an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Adamantanoylindoles include, but are not limited to:</p> <ul style="list-style-type: none"> <li>(1) adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone (AM1248), or</li> <li>(2) adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-001);</li> </ul> <p>Carbazole Ketone: Any compound containing (9H-carbazole-3-yl)methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole Ketones include, but are not limited to, naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018).</p>	<p>5/12/2015 – enacted (2015 Laws Chapter 305); effective 8/29/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Oklahoma</p> <p>2015 HB 1616 (Continued) (Page 3 of 3)</p>	<p>Adds the following substances to Schedule I:</p> <p>Benzimidazole Ketone: Any compound containing (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include, but are not limited to:</p> <p>(1) naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone (JWH-018 benzimidazole analog), or</p> <p>(2) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA).</p> <p>Removes “Hydrocodone with another active ingredient” from Schedule III.</p> <p>Adds Suvorexant to Schedule IV.</p>	<p>5/12/2015 – enacted (2015 Laws Chapter 305); effective 8/29/2015.</p>
<p>Oregon</p>	<p>No pending proposed regulations.</p>	

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Pennsylvania 2015 HB 608</p>	<p>Adds the following substances to Schedule I:            (1) ACETYL FENTANYL;            (2) 3,4-METHYLENEDIOXYMETHAMPHETAMINE;            (3) METHOXETAMINE.</p> <p>Makes extensive changes in Schedule I to how synthetic cannabinoids are defined and which ones are listed.</p> <p>Adds LISDEXAMFETAMINE to Schedule II.</p> <p>Removes the following combination products from Schedule III:            (1) NOT MORE THAN 300 MILLIGRAMS OF DIHYDROCODEINONE PER 100 MILLILITERS OR NOT MORE THAN 15 MILLIGRAMS PER DOSAGE UNIT, WITH A FOURFOLD OR GREATER QUANTITY OF AN ISOQUINOLINE ALKALOID OF OPIUM;            (2) NOT MORE THAN 300 MILLIGRAMS OF DIHYDROCODEINONE PER 100 MILLILITERS OR NOT MORE THAN 15 MILLIGRAMS PER DOSAGE UNIT, WITH ONE OR MORE ACTIVE, NONNARCOTIC INGREDIENTS IN RECOGNIZED THERAPEUTIC AMOUNTS.</p> <p>Adds the following substances to Schedule IV:            (1) ZOPICLONE;            (2) CARISOPRODOL;            (3) TRAMADOL.</p> <p>Adds Pregabalin to Schedule V and moves Buprenorphine from Schedule V to Schedule III.</p>	<p>6/2/2015 – recommitted to Rules Committee.</p>
<p>Pennsylvania 2015 HB 1052</p>	<p>Provides that “any synthetic cannabinoid or cathinone not regulated by the Federal Food and Drug Administration or by State law that binds to a cannabinoid receptor or mimics the pharmacological response of a Schedule I or II controlled substance shall be considered a Schedule II substance under State law.”</p>	<p>4/27/2015 – referred to Judiciary Committee.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Rhode Island  2015 SB 509	Adds the following substances to Schedule I: “Any synthetic cannabinoid or cathinone not regulated by the federal Food and Drug Administration, or by state law that binds to the cannabinoid receptor(s) and/or mimics the pharmacological response of a schedule I or II controlled substance as determined by the process described in § 21-28-7.0 shall be considered a schedule I substance.”	3/3/2015 – committee recommends measure be held for further study.
South Carolina  2015 HB 4123	Adds the following substances to Schedule I: “any other material, compound, mixture, or preparation that binds to the cannabinoid receptor or mimics the pharmacological response of a Schedule I or II controlled substance, except as exempted pursuant to state law for a person or entity that possesses a chemical formula defined as a scheduled drug pursuant to this subsection for a lawful purpose.”	5/5/2015 – introduced and referred to Committee on Judiciary.
South Dakota  2015 SB 61 (Page 1 of 3)	Revises the description of synthetic cannabinoids in Schedule I as follows (text added in underline): Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed as a controlled substance in another schedule, is not an FDA-approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues, <u>modifications of the indole ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or propionaldehyde structure</u> , and salts of isomers, homologues, <u>and modifications</u> , unless specifically excepted, whenever the existence of these salts, isomers, homologues, modifications, and salts of isomers, homologues, <u>and modifications</u> is possible within the specific chemical designation:  Makes slight changes to the following descriptions in Schedule I: Naphthoylindoles, Naphthylmethylindoles, Phenylacetylindoles, Benzoylindoles, Naphthoylpyrroles, Naphthylmethylindenenes, Cyclohexylphenols, Substituted Acetylindoles, Substituted Carboxamide Indole	2/18/2015 – enacted (2015 Laws Chapter 180); effective 2/18/2015.

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.



State and Bill Number	Description	Status/Date of Last Action
<p>South Dakota</p> <p>2015 SB 61 (Continued) (Page 2 of 3)</p>	<p>Adds the following paragraph to Schedule I:</p> <p>Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent whether or not further substituted on the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde substituent to any extent and whether or not further substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, tetrahydropyranymethyl, benzyl, or halo benzyl group whether or not further substituted on the indole ring to any extent.</p> <p>Adds the following substances to Schedule II:</p> <ol style="list-style-type: none"> <li>(1) Morphine, except when it meets subdivision 34-20B-23(8);</li> <li>(2) Hydrocodone (Dihydrocodeinone);</li> <li>(3) Codeine, except when it meets subdivision 34-20B-23(1), 34-20B-23(2), or 34-20B-26(1);</li> <li>(4) Dihydrocodeine, except when it meets subdivision 34-20B-23(5) or 34-20B-26(2);</li> <li>(5) Ethylmorphine, except when it meets subdivision 34-20B-23(6) or 34-20B-26(3);</li> <li>(6) Oxycodone; and</li> <li>(7) Hydromorphone.</li> </ol> <p>Removes the following two combination products from Schedule III:</p> <ol style="list-style-type: none"> <li>(1) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of isoquinoline alkaloid of opium; and</li> <li>(2) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts.</li> </ol>	<p>2/18/2015 – enacted (2015 Laws Chapter 180); effective 2/18/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>South Dakota</p> <p>2015 SB 61 (Continued) (Page 2 of 3)</p>	<p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) Alprazolam;</li> <li>(2) Midazolam;</li> <li>(3) Temazepam;</li> <li>(4) Alfaxalone, 5[alpha]-pregnan-3[alpha]-ol-11,20-dione, including its salts, isomers, and salts of isomers;</li> <li>(5) Tramadol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers; and</li> <li>(6) Suvorexant, including its salts, isomers, and salts of isomers.</li> </ul> <p>Amends Schedule IV to change the phrase “not more than 0.5 milligrams of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit” to “not more than 1 milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit.”</p>	<p>2/18/2015 – Signed by Governor; effective 2/18/2015.</p>
<p>Tennessee</p> <p>2015 HB 287</p>	<p>Substituted by 2015 SB 318.</p>	<p>4/8/2015 – substituted by companion bill.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMSDDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Tennessee</p> <p>2015 SB 318 (Page 1 of 6)</p>	<p>Adds the following hallucinogenic substances to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36;</li> <li>(2) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82;</li> <li>(3) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5;</li> <li>(4) 3,4-Methylenedioxy-N-methylcathinone; Other names: Methylone;</li> <li>(5) 4-Methylmethcathinone; Other names: Mephedrone; Methpadrone; 4-MMC;</li> <li>(6) 3,4-Methylenedioxypropylvalerone; Other names: MDPV;</li> <li>(7) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);</li> <li>(8) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);</li> <li>(9) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);</li> <li>(10) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);</li> <li>(11) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);</li> <li>(12) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);</li> <li>(13) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);</li> <li>(14) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);</li> <li>(15) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);</li> <li>(16) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: UR-144; 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole;</li> <li>(17) [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 5-fluoro-UR-144; 5-F-UR-144; XLR-11; 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropyl)indole;</li> <li>(18) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: APINACA; AKB-48;</li> </ol>	<p>4/24/2015 – enacted (2015 Laws Chapter 302); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 2 of 6)</p>	<p>Adds the following hallucinogenic substances to Schedule I:</p> <p>(19) 25H-NBOMe, being any compound structurally derived from 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine structure with substitution in either phenyl ring to any extent.</p> <p>Adds "ET" and "Trip" as other names for Alpha-ethyltryptamine; specifies that "Constituent of 'Peyote' cacti" is another name for Mescaline; specifies that Psilocybin and Psilocyn are constituents of magic mushrooms; and removes the following from the schedule: 55H-NBOMe, being any compound structurally derived from 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine structure with substitution in either phenyl ring to any extent; including, but not limited to 25I-NBOMe, 25-B-NBOMe, or 25C-NBOMe. This bill also revises from "TCP" to "TCPy" the other name for 1-[1-(2-Thienyl)cyclohexyl]piperidine.</p> <p>Adds the following stimulants to Schedule I:</p> <p>(1) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one;</p> <p>(2) Alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one;</p> <p>(3) Butylone, its optical, positional, and geometric isomers, salts, and salts of isomers;</p> <p>(4) Alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one;</p> <p>(5) Alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one;</p> <p>(6) Butylone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one;</p>	<p>4/24/2015 – enacted (2015 Laws Chp. 302); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 3 of 6)</p>	<p>Adds the following stimulants to Schedule I:</p> <p>(7) 3-Fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one;</p> <p>(8) 4-Fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-one;</p> <p>(9) 4-Methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one;</p> <p>(10) 4-Methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one;</p> <p>(11) Naphyrone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one;</p> <p>(12) Pentedrone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one;</p> <p>(13) Pentylone, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one.</p> <p>Adds "constituent of Catha edulis or 'Khat' plant" under "other names" for Cathinone.</p> <p>(1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);</p> <p>(2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog);</p> <p>(3) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);</p> <p>(4) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);</p> <p>(5) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);</p> <p>(6) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);</p>	<p>4/24/2015 – enacted (2015 Laws Chp. 302); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 4 of 6)</p>	<p>Adds the following “Cannabimimetic agents” to Schedule I:</p> <ul style="list-style-type: none"> <li>(7) 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);</li> <li>(8) 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);</li> <li>(9) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);</li> <li>(10) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);</li> <li>(11) 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201);</li> <li>(12) 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);</li> <li>(13) 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4);</li> <li>(14) 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole 7008 (SR-18 and RCS-8);</li> <li>(15) 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203);</li> <li>(16) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers; Other name: AB-FUBINACA;</li> <li>(17) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers; Other name: ADB-PINACA;</li> <li>(18) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: 5-fluoro-PB-22; 5F-PB-22;</li> </ul> <p>Adds the following “Cannabimimetic agents” to Schedule I:</p> <ul style="list-style-type: none"> <li>(1) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers; Other names: PB-22; QUPIC.</li> </ul> <p>In regard to Schedule III, adds Perampanel, and its salts, isomers, and salts of isomers. This bill also makes a change to the chemical name under "other names" for Ketamine.</p>	<p>4/24/2015 – enacted (2015 Laws Chp. 302); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 5 of 6)</p>	<p>In regard to Schedule III, Narcotic drugs, present law includes any material, compound, mixture, or preparation containing the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities:</p> <ol style="list-style-type: none"> <li>(1) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;</li> <li>(2) Not more than 300 milligrams of dihydrocodeinone (hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts; and</li> <li>(3) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.</li> </ol> <p>This bill deletes the above provisions and instead includes: not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.</p> <p>In regard to Schedule III, Anabolic steroids, this bill adds the following to the schedule:</p> <ol style="list-style-type: none"> <li>(1) Chlorotestosterone (which, under present law, is listed as a "other name" for Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);</li> <li>(2) Methandranone;</li> <li>(3) Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one);</li> <li>(4) Prostanazol (17[beta]-hydroxy-5[alpha]-androstan[3,2-c]pyrazole); and</li> <li>(5) Stanolone.</li> </ol>	<p>4/24/2015 – enacted (2015 Laws Chp. 302); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Tennessee</p> <p>2015 HB 287 (Continued) (Page 6 of 6)</p>	<p>Adds the following substances to Schedule IV:</p> <ul style="list-style-type: none"> <li>(1) Alfaxalone;</li> <li>(2) Suvorexant;</li> <li>(3) Dexfenfluramine;</li> <li>(4) Lorcaserin.</li> </ul> <p>Adds Ezogabine to Schedule V.</p> <p>Removes the following compounds that are structurally derived from 2-amino-1-phenyl-1-propanone by modification:</p> <ul style="list-style-type: none"> <li>(1) 3,4-methylenedioxymethcathinone (Methylone);</li> <li>(2) 3,4-methylenedioxypyrovalerone (MDPV);</li> <li>(3) 4-methylmethcathinone (Mephedrone, Methpadrone, 4-MMC);</li> <li>(4) 4-fluoromethcathinone (Flephedrone);</li> <li>(5) 3-fluoromethcathinone (3-FMC);</li> <li>(6) 2-(methylamino)-1-phenylpropan-1-one (Ephedrone);</li> <li>(7) alpha-Pyrrolidinopentiophenone (alpha-PVP);</li> <li>(8) Naphthylpyrovalerone (Naphyrone);</li> <li>(9) beta-Keto-N-methylbenzodioxolylpropylamine (Butylone);</li> <li>and</li> <li>(10) beta-Keto-N-methylbenzodioxolylpentanamine (Pentylone).</li> </ul> <p>The state Senate adopted an amendment passed Senate Bill 318, as amended, adding 25H-NBOMe, being any compound structurally derived from 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine structure with substitution in either phenyl ring to any extent, to the list of Schedule I, Hallucinogenic substances; removes F-PB-22 from the list of prohibited synthetic cannabinoids; and clarifies that derivatives of hydroxymitragynine are controlled substances.</p>	<p>4/24/2015 – enacted (2015 Laws Chp. 302); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Tennessee</p> <p>2015 SB 932</p>	<p>Adds the following substances to Schedule I:</p> <ul style="list-style-type: none"> <li>(1) Naphthoylindazoles, being any compound structurally derived from 3-(1-naphthoyl) indazole structure with substitution at the nitrogen atom of the indazole ring, whether or not further substituted in the indazole ring to any extent, whether or not substituted in the naphthyl ring to any extent; including, but not limited to THJ-2201;</li> <li>(2) Methylindazolecarboxamidobutanoate, being any compound structurally derived from methyl-2-(indazole-3-carboxamido) butanoate structure with substitution at the nitrogen atom of the indazole ring whether or not further substituted in the indazole ring to any extent, whether or not substituted in the butanyl or methyl chain around the ester to any extent; including, but not limited to AMB and fluoro-AMB;</li> <li>(3) Naphthalenyndolecarboxylates, being any compound structurally derived from a naphthalen-1-yl 1H-indole-3-carboxylate structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthalene ring to any extent; including, but not limited to NM-2201.</li> </ul> <p>Changes the term "Quinolinyndolecarboxesters" in Schedule I to "Quinolinyndolecarboxylate."</p>	<p>5/8/2015 – enacted (2015 Laws Chapter 401); effective 7/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>40 TexReg 1744</p>	<p>Annual republishing of controlled substances schedules in Texas Register contains the following changes.</p> <p>Substances added to Schedule I:</p> <ol style="list-style-type: none"> <li>(1) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: PB-22; QUPIC);</li> <li>(2) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 5-fluoro-PB-22; 5F-PB-22);</li> <li>(3) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: AB-FUBINACA);</li> <li>(4) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: ADB-PINACA);</li> <li>(5) 4-methyl-N-ethylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one);</li> <li>(6) 4-methyl-alpha-pyrrolidinopropiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-MePPP; MePPP; 4-methyl-[alpha]-pyrrolidinopropiophenone; 1-(4-methylpenyl)-2-(pyrrolidin-1-yl)-propan-1-one);</li> <li>(7) alpha-pyrrolidinopentiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one);</li> <li>(8) Butylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one);</li> <li>(9) Pentedrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one);</li> </ol>	<p>4/10/2015 – effective</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>40 TexReg 1744</p>	<p>Substances added to Schedule I:</p> <p>(10) Pentylone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one);</p> <p>(11) 4-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 4-FMC; flephedrone; 1-(4-flouropheryl)-2-(methylamino)propan-1-one);</p> <p>(12) 3-fluoro-N-methylcathinone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: 3-FMC; 1-(3-fluorophenyl)-2-(methylamino)propan-1-one);</p> <p>(13) Naphyrone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: naphthylpyrovalerone; 1-naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one);</p> <p>(14) alpha-pyrrolidinobutiophenone, its optical, positional, and geometric isomers, salts and salts of isomers (Other names: [alpha]-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one).</p> <p>Perampanel is added to Schedule III.</p> <p>The following substances are added to Schedule IV:</p> <p>(1) Alfaxalone;</p> <p>(2) Fospropofol;</p> <p>(3) Suvorexant;</p> <p>(4) Tramadol.</p>	<p>4/10/2015 – effective</p>
<p>Texas</p> <p>40 TexReg 2007</p>	<p>Amendment that: (1) temporarily adds AB-CHMINACA, AB-PINACA and THJ-2001 into Schedule I; and (2) removes of naloxegol from Schedule II.</p>	<p>4/24/2015 – effective.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

State and Bill Number	Description	Status/Date of Last Action
<p>Texas</p> <p>2015 SB 172 (Page 1 of 5)</p>	<p>Adds the following substances to Penalty Group 1-A: Compounds structurally derived from 2,5-dimethoxyphenethylamine by substitution at the 1-amino nitrogen atom with a benzyl substituent, including: (A) compounds further modified by: (i) substitution in the phenethylamine ring at the 4- position to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents); or (ii) substitution in the benzyl ring to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents); and (B) by example, compounds such as:</p> <ol style="list-style-type: none"> <li>(1) 4-Bromo-2,5-dimethoxy-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25B-NBOMe, 2C-B-NBOMe);</li> <li>(2) 4-Chloro-2,5-dimethoxy-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25C-NBOMe, 2C-C-NBOMe);</li> <li>(3) 2,5-Dimethoxy-4-methyl-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25D-NBOMe, 2C-D-NBOMe);</li> <li>(4) 4-Ethyl-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine (trade or other names: 25E-NBOMe, 2C-E-NBOMe);</li> <li>(5) 2,5-Dimethoxy-N-(2- methoxybenzyl)phenethylamine (trade or other names: 25H-NBOMe, 2C-H-NBOMe);</li> <li>(6) 4-Iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine (trade or other names: 25I-NBOMe, 2C-I-NBOMe);</li> <li>(7) 4-Iodo-2,5-dimethoxy-N- benzylphenethylamine (trade or other name: 25I-NB);</li> <li>(8) 4-Iodo-2,5-dimethoxy-N-(2,3- methylenedioxybenzyl) phenethylamine (trade or other name: 25I-NBMD);</li> <li>(9) 4-Iodo-2,5-dimethoxy-N-(2- fluorobenzyl)phenethylamine (trade or other name: 25I-NBF);</li> <li>(10) 4-Iodo-2,5-dimethoxy-N-(2- hydroxybenzyl) phenethylamine (trade or other name: 25I-NBOH);</li> <li>(11) 2,5-Dimethoxy-4-nitro-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25N-NBOMe, 2C-N-NBOMe); and</li> <li>(12) 2,5-Dimethoxy-4-(n)-propyl-N-(2- methoxybenzyl) phenethylamine (trade or other names: 25P-NBOMe, 2C-P-NBOMe).</li> </ol>	<p>5/22/2015 – enacted (2015 Laws Chapter 64); effective 9/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>2015 SB 172 (Continued) (Page 2 of 5)</p>	<p>Removes the following substances from Penalty Group 2:</p> <ol style="list-style-type: none"> <li>(1) [alpha-ethyltryptamine;</li> <li>(2) [alpha-methyltryptamine;</li> <li>(3) [4-bromo-2, 5-dimethoxyamphetamine (some trade or other names: 4-bromo-2, 5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2, 5-DMA);</li> <li>(4) [4-bromo-2, 5-dimethoxyphenethylamine;]</li> <li>(5) [Bufotenine (some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; 5-hydroxy-N, N- dimethyltryptamine; mappine);</li> <li>(6) [Diethyltryptamine (some trade and other names: N, N-Diethyltryptamine, DET);]</li> <li>(7) [2, 5-dimethoxy-4-ethylamphetamine (trade or other name: DOET);</li> <li>(8) [2, 5-dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7);]</li> <li>(9) [Dimethyltryptamine (trade or other name: DMT);]</li> </ol> <p>Adds the following substances to Penalty Group 2:</p> <ol style="list-style-type: none"> <li>(1) 5-(2-aminopropyl)benzofuran (5-APB);</li> <li>(2) 6-(2-aminopropyl)benzofuran (6-APB);</li> <li>(3) 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB);</li> <li>(4) 6-(2-aminopropyl)-2,3-dihydrobenzofuran (6-APDB);</li> <li>(5) 5-(2-aminopropyl)indole (5-IT,5-API);</li> <li>(6) 6-(2-aminopropyl)indole (6-IT,6-API);</li> <li>(7) 1-(benzofuran-5-yl)-N-methylpropan-2-amine (5-MAPB);</li> <li>(8) 1-(benzofuran-6-yl)-N-methylpropan-2-amine (6-MAPB);</li> <li>(9) Benzothiophenylcyclohexylpiperidine (BTCP);</li> <li>(10) 8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- 4-ethanamine (trade or other name: Bromo-DragonFLY);</li> <li>(11) Desoxypipradrol (2-benzhydrylpiperidine);</li> <li>(12) Diphenylprolinol (diphenyl(pyrrolidin-2-yl) methanol, D2PM);</li> <li>(13) 2-ethylamino-2-(3-methoxyphenyl)cyclohexanone (trade or other name: methoxetamine);</li> <li>(14) 5-iodo-2-aminoindane (5-IAI);</li> <li>(15) 4-methoxymethamphetamine (PMMA);</li> <li>(16) 2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone (some trade and other names: 2-MeO-ketamine; methoxyketamine);</li> </ol>	<p>5/22/2015 – enacted (2015 Laws Chapter 64); effective 9/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>2015 SB 172 (Continued) (Page 3 of 5)</p>	<p>Adds the following substances to Penalty Group 2:</p> <p>(17) 5,6-methylenedioxy-2-aminoindane (MDAI);</p> <p>(18) Etaqualone and its salts;</p> <p>(19) alpha-Methylamino-valerophenone (Also known as Pentedrone);</p> <p>(20) (5) any compound structurally derived from tryptamine (3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine;</p> <p>(21) (A) by modification in any of the following ways:</p> <p>(22) (i) by substitution at the amine nitrogen atom of the sidechain to any extent with alkyl or alkenyl groups or by inclusion of the amine nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;</p> <p>(23) (ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain (alpha-position) with an alkyl or alkenyl group;</p> <p>(24) (iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents; or</p> <p>(25) (iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent; and</p> <p>(26) (B) including:</p> <p>(27) (i) ethers and esters of the controlled substances listed in this subdivision; and</p> <p>(28) (ii) by example, compounds such as:</p> <p>(29) alpha-ethyltryptamine;</p> <p>(30) alpha-methyltryptamine;</p> <p>(31) Bufotenine (some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; 5-hydroxy-N, N- dimethyltryptamine; mappine);</p> <p>(32) Diethyltryptamine (some trade and other names: N, N-Diethyltryptamine, DET);</p> <p>(33) Dimethyltryptamine (trade or other name: DMT);</p> <p>(34) 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DiPT);</p> <p>(35) O-Acetylpsilocin (Trade or other name: 4-Aco-DMT);</p>	<p>5/22/2015 – enacted (2015 Laws Chapter 64); effective 9/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>2015 SB 172 (Continued) (Page 4 of 5)</p>	<p>Adds the following substances to Penalty Group 2:</p> <p>(36) Psilocin; and</p> <p>(37) Psilocybin; (6) 2,5-Dimethoxyphenethylamine and any compound structurally derived from 2,5-Dimethoxyphenethylamine by substitution at the 4-position of the phenyl ring to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents), including, by example, compounds such as:</p> <p>(38) 4-Bromo-2,5-dimethoxyphenethylamine (trade or other name: 2C-B);</p> <p>(39) 4-Chloro-2,5-dimethoxyphenethylamine (trade or other name: 2C-C);</p> <p>(40) 2,5-Dimethoxy-4-methylphenethylamine (trade or other name: 2C-D);</p> <p>(41) 4-Ethyl-2,5-dimethoxyphenethylamine (trade or other name: 2C-E);</p> <p>(42) 4-Iodo-2,5-dimethoxyphenethylamine (trade or other name: 2C-I);</p> <p>(43) 2,5-Dimethoxy-4-nitrophenethylamine (trade or other name: 2C-N);</p> <p>(44) 2,5-Dimethoxy-4-(n)-propylphenethylamine (trade or other name: 2C-P);</p> <p>(45) 4-Ethylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-2);</p> <p>(46) 4-Isopropylthio-2,5-dimethoxyphenethylamine (trade or other name: 2C-T-4); and</p> <p>(47) 2,5-Dimethoxy-4-(n)-propylthiophenethylamine (trade or other name: 2C-T-7); and</p> <p>(48) (7) 2,5-Dimethoxyamphetamine and any compound structurally derived from 2,5-Dimethoxyamphetamine by substitution at the 4-position of the phenyl ring to any extent (including alkyl, alkoxy, alkylendioxy, haloalkyl, or halide substituents), including, by example, compounds such as:</p> <p>(49) 4-Ethylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-2);</p> <p>(50) 4-Isopropylthio-2,5-dimethoxyamphetamine (trade or other name: Aleph-4);</p> <p>(51) 4-Bromo-2,5-dimethoxyamphetamine (trade or other name: DOB);</p>	<p>5/22/2015 – enacted (2015 Laws Chapter 64); effective 9/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>2015 SB 172 (Continued) (Page 5 of 5)</p>	<p>Adds the following substances to Penalty Group 2:</p> <p>(52) 4-Chloro-2,5-dimethoxyamphetamine (trade or other name: DOC); 2,5-Dimethoxy-4-ethylamphetamine (trade or other name: DOET);</p> <p>(53) 4-Iodo-2,5-dimethoxyamphetamine (trade or other name: DOI);</p> <p>(54) 2,5-Dimethoxy-4-methylamphetamine (trade or other name: DOM);</p> <p>(55) 2,5-Dimethoxy-4-nitroamphetamine (trade or other name: DON);</p> <p>(56) 4-Isopropyl-2,5-dimethoxyamphetamine (trade or other name: DOIP); and</p> <p>(57) 2,5-Dimethoxy-4-(n)-propylamphetamine (trade or other name: DOPR).</p>	<p>5/22/2015 – enacted (2015 Laws Chapter 64); effective 9/1/2015.</p>
<p>Texas</p> <p>2015 SB 173 (Page 1 of 2)</p>	<p>Adds the following substances to Penalty Group 2-A:</p> <p>(1) WIN-55, ;</p> <p>(2) Cyclohexylphenol.</p> <p>(3) JWH-337;</p> <p>(4) JWH-344;</p> <p>(5) Cannabinol</p> <p>(6) Tetramethylcyclopropyl thiazole: any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including: A-836,339;</p> <p>(7) any compound containing a core component substituted at the 1-position to any extent, and substituted at the 3-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:</p> <p>a. Naphthoylindane;</p>	<p>5/22/2015 – enacted (2015 Laws Chapter 65); effective 9/1/2015.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Texas</p> <p>2015 SB 173 (Continued) (Page 2 of 2)</p>	<p>Adds the following substances to Penalty Group 2-A:</p> <ul style="list-style-type: none"> <li>b. Naphthoylindazole (THJ-018);</li> <li>c. Naphthyl methyl indene (JWH-171);</li> <li>d. Naphthoylindole (JWH-018);</li> <li>e. Quinolinoyl pyrazole carboxylate (Quinolinyll fluoropentyl fluorophenyl pyrazole carboxylate);</li> <li>f. Naphthoyl pyrazolopyridine; and</li> <li>g. Naphthoylpyrrole (JWH-030);</li> </ul> <p>(8) any compound containing a core component substituted at the 1-position to any extent, and substituted at the 2-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including: Naphthoylbenzimidazole (JWH-018 Benzimidazole); and Naphthoylimidazole;</p> <p>(9) any compound containing a core component substituted at the 3-position to any extent, and substituted at the 2-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including: Naphthoyl benzothiazole; and</p> <p>(10) any compound containing a core component substituted at the 9-position to any extent, and substituted at the 3-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including: Naphthoylcarbazole (EG-018).</p> <p>Deletes numerous individual listings from group.</p>	<p>5/22/2015 – enacted (2015 Laws Chapter 65); effective 9/1/2015.</p>
<p>Texas</p> <p>2015 SB 1583</p>	<p>Adds a provision to Schedule I that it includes “any synthetic cannabinoid or cathinone designer drug that is not regulated by the United States Food and Drug Administration or by the laws of this state but that is similar by structure or pharmacological effect to a Schedule I or II controlled substance that is regulated under federal law or the laws of this state.”</p> <p>Examples include “substances that are generated using a three-component pharmacophore model. Synthetic cannabinoid designer drugs that contain one or more components of a controlled substance in Schedule I or II under federal or state law are analogues of Schedule I or II controlled substances.”</p>	<p>5/26/2015 – placed on general state calendar.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
Utah	No pending proposed legislation.	
Vermont  ADC 12-5-23:I, II, III, IV, V, VI, VII (Page 1 of 4)	<p>Vermont does not have a published list of controlled substance schedules, but there is a published list of “regulated drugs” (Vt. Admin. Code § 12-5-23:I to VIII).</p> <p>Additions to stimulant drugs:</p> <ul style="list-style-type: none"> <li>(1) 2-AI; 2-Aminoindane;</li> <li>(2) 2-methylmethcathinone; 2-MMC;2-Methyl MC;</li> <li>(3) 3, 4 methylenedioxy-methamphetamine (MDMA);</li> <li>(4) 4-bromomethcathinone; 4-BMC;</li> <li>(5) 4-chloromethcathinone;4-CMC;Clephedrone;</li> <li>(6) 4-MPD; 4-Methyl-Pentedrone;</li> <li>(7) 5-IAI; 5-Iodo-2-Aminoindane;</li> <li>(8) a-ethylaminopentiophenone;</li> <li>(9) bk-2C-B; bk-4 Bromo-2,5-dimethoxyphenethylamine;</li> <li>(10) Cathine;</li> <li>(11) Cathinone;</li> <li>(12) M11; dimethylone;</li> <li>(13) MBPV; 5-DBFPN; 1-(2,3-dihydrobenzofuran-5-yl)-2-(pyrrolidin-1-yl)pentan-1-on;</li> <li>(14) Mephtetramine; MTA;</li> <li>(15) MT-45; IC-6; NSC 299236; 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine;</li> <li>(16) NM2AI; NM-2AI; N-Methyl-2-Aminoindane;</li> <li>(17) Pyrovalerone; (Valerophenone, Thymergix, Centroton).</li> </ul> <p>Additions to depressant drugs: Phenazepam; BD 98; Fenazepam.</p> <p>Additions to narcotic drugs:</p> <ul style="list-style-type: none"> <li>(1) Acetyl-fentanyl;</li> <li>(2) Cocaine;</li> <li>(3) Tilidine;</li> <li>(4) Tramadol.</li> </ul>	5/29/2015 – public hearing on proposed regulations held.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Vermont</p> <p>ADC 12-5-23:I, II, III, IV, V, VI, VII (Continued) (Page 2 of 4)</p>	<p>Additions to hallucinogenic drugs:</p> <ul style="list-style-type: none"> <li>(1) 1-(4-methoxybenzoyl)-4-methylpiperazine; MEXP; Methoxypiperamide;</li> <li>(2) 5-EAPB; 5-(2-Ethylaminopropyl)Benzofuran;</li> <li>(3) 5F-AMB; 5-fluoro AMP;</li> <li>(4) 5F-ADBICA; 5-fluoro ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;</li> <li>(5) 5F-AKB48; AKB48 N-(5-fluoropentyl) analog; 5f-APINACA; APINACA 5-fluoropentyl analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;</li> <li>(6) 5F-MN-018;5-fluoro MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide;</li> <li>(7) 5F-MN24; 5-fluoro NNEI; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide;</li> <li>(8) 5F-SDB-005; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate;</li> <li>(9) 5F-THJ-2201; (1-(5-fluoropentyl)-1H-indazol-3-yl) (naphthalen-1-yl) methanone;</li> <li>(10) 5FAB-FUBINACA;</li> <li>(11) 5FAB-PINACA; AB-PINACA 5 fluoro analog; (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;</li> <li>(12) 5FPB22; 5-fluoro PB-22; 5-fluoro QUPIC; 1-(5-fluoropentyl)-8-quinolinyl ester-1Hindole-3-carboxylic acid;</li> <li>(13) 5FSDB-006; 5-fluoro SDB-006; N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide;</li> <li>(14) 5-IT; 5-(2-aminopropyl)indole;</li> <li>(15) 5-MAPB; 5-(2-Methylaminopropyl) Benzofuran;</li> <li>(16) 5-MeO-MDA; 5-methoxy-3, 4-methylenedioxy amphetamine;</li> <li>(17) A1 dodeca-2E, 4E, 8Z, 10Z – tetraenoic acid isobutyl amide;</li> <li>(18) A2 dodeca-2E, 4E, dienoic acid idobutylamide;</li> <li>(19) AB-CHMINACA; N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;</li> </ul>	<p>5/29/2015 – public hearing on proposed regulations held.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDDL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Vermont  ADC 12-5-23:I, II, III, IV, V, VI, VII (Continued) (Page 3 of 4)	Additions to hallucinogenic drugs: (20) AB-PINACA; (21) ACEA; N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide; (22) ACPA; N-cyclopropyl-5Z,8Z,11Z,14Z-eicosatetraenamide (23) ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide; (24) AL-LAD; 6-allyl-6-nor-LSD; 6-Allyl-6-nor-lysergic acid diethylamide; (25) AM630; Iodopravadoline; [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanon; (26) AM-4113; (27) ASDB-FUB-187 BAY 38-7271; (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate; (28) EAM-2201; JWH-210 N-(5 fluoropentyl) analog; (4-ethyl-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-methanone; (29) EG-018; naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl) methanone; (30) FDU-PB-22; naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (31) FAB-144; (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; (32) F-UPB-22; (33) FUB-AKB48; AKB48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl) -1H-indazole-3-carboxamide; (34) FUB-PB22; FUB-PB-22; ; quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate; (35) FUBIMINA; AM2201 Benzimidazole analog; BIM-2201, FTHJ; (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl) (naphthalen-1-yl)methanone; (36) HDMP-28; Methylnaphthidate (37) L-759,633; 3-(1,1-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-methoxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran;	5/29/2015 – public hearing on proposed regulations held.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>Vermont</p> <p>ADC 12-5-23:I, II, III, IV, V, VI, VII (Continued) (Page 4 of 4)</p>	<p>Additions to hallucinogenic drugs:</p> <p>(38) L-759,656;</p> <p>(39) LSZ; Lysergic acid 2,4-dimethylazetidide, Diazedine, Lambda, LA-SS-AzLysergic acid diethylamide;</p> <p>(40) MA-CHMINACA; AMB N-METHYLCYCLOHEXYL ANALOG, AB-CHMINACA, MAB-AB-CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-Lvalinate;</p> <p>(41) MDMB-CHMINACA; (S)-MDMB-CHMINACA; N-[[1-(cyclohexylmethyl)-1Hindazol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester;</p> <p>(42) Mepirapim; JWH-018-4(methylpiperazine); (4-methylpiperazin-1-yl)(1-pentyl-1Hindol-3-yl)methanone, monohydrochloride</p> <p>(43) MB-2201; I-AMB; methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate</p> <p>(44) MMB-CHMINACA; (2S)-methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-ylcarbonylamino)-3,3-dimethylbutanoate</p> <p>(45) MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide</p> <p>(46) MN-24; NNEI; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; AM-6527</p> <p>(47) Mitragynine</p> <p>(48) NM2201</p> <p>(49) SDB-005; naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate</p> <p>(50) SR 144528; 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)- 1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide</p> <p>(51) STS-144; (1-(5-fluoropentyl)-1H-indol-3-yl)(pyridin-3-yl)methanone</p> <p>(52) THJ-018; JWH-018 Indazole analog; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)- methanone</p> <p>(53) THJ-2201; Fluoropentyl JWH-018 Indazole, AM2201 indazole analog, 5-Fluoro</p> <p>(54) W-15; (E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide</p>	<p>5/29/2015 – public hearing on proposed regulations held.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Virginia 2015 HB 1564	Adds the following substances to Schedule I: (1) 3,4-methylenedioxy-N,N-dimethylcathinone (other names: Dimethylone, bk-MDDMA); (2) N-3-methyl-1-(2-hydroxy-2-phenethyl)4-piperidyl]-N-phenylpropanamide (other name: beta-hydroxy-3-methylfentanyl); (3) N-(4-fluorophenyl)-N-1-(2-phenethyl)-4-piperidinyl]-propanamide; (4) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name: AB-CHMINACA); (5) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name: 5-fluoro-AB-PINACA).	4/15/2015 – enacted (2015 Laws Chapter 726); effective 7/1/2015.
Virginia 2015 SB 1380	Same as 2015 HB 1564.	4/15/2015 – enacted (2015 Laws Chapter 727); effective 7/1/2015.
Washington 2015 HB 1552	Adds provision that industrial hemp is excepted from the categories of controlled substances in the schedules.	6/28/2015 – by resolution, reintroduced and retained in present status.
Washington 2015 HB 2136	Among many other provisions, amends the definition of tetrahydrocannabinol in Schedule I in similar fashion as 2015 SB 5673.	6/27/2015 – enrolled bill sent to Governor.

Yellow highlighted text indicates legislation that has been enacted into law.  
 Red text indicates that the legislature presently is not in session.  
 Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>Washington</p> <p>2015 SB 5434 (Page 1 of 2)</p>	<p>Adds the following synthetic cannabimimetics substances to Schedule I:</p> <p>Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p> <p>Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p> <p>Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p> <p>Naphthylmethylindenes: Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;</p>	<p>6/28/2015 – by resolution, reintroduced and retained in present status.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<u>State and Bill Number</u>	<u>Description</u>	<u>Status/Date of Last Action</u>
<p>Washington</p> <p>2015 SB 5434 (Continued) (Page 2 of 2)</p>	<p>Adds the following synthetic cannabimimetics substances to Schedule I:</p> <p>Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;</p> <p>Adds the following synthetic cannabimimetics substances to Schedule I:</p> <p>Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent;</p> <p>Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; (viii) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: Some trade or other names: WIN 55,212-2;</p> <p>Adds (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3- (2-methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c]chromen-1-ol: Some trade or other names: HU-210 to Schedule I.</p>	<p>6/28/2015 – by resolution, reintroduced and retained in present status.</p>

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.



<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Washington 2015 SB 5673	Adds the following provision to the definition of tetrahydrocannabinols in Schedule I:  “That is chemically synthesized and either: (1) Has been demonstrated to have binding activity at one or more cannabinoid receptors; or (2) Is a chemical analog or isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors.”	6/28/2015 – by resolution, reintroduced and retained in present status.
Washington 2015 HB 6136	Among many other provisions, amends the definition of tetrahydrocannabinol in Schedule I in similar fashion as 2015 SB 5673.	6/28/2015 – by resolution, reintroduced and retained in present status.
West Virginia 2015 HB 2611	Adds ephedrine, pseudoephedrine and phenylpropanolamine to Schedule IV.	2/5/2015 – referred to Health and Human Services Committee.
West Virginia 2015 HB 2931 (Page 1 of 2)	Adds the following hallucinogenic substances to Schedule I: (1) N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine [25B-NBOMe]; (2) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine [25C-NBOMe]; (3) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine [25I-NBOMe];  Adds the following tryptamines to Schedule I: (1) 5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT); (2) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); (3) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT); (4) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); (5) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT); (6) 5-methoxy- and -methyltryptamine (5-MeO-AMT);	4/2/2015 – enacted (2015 Laws Chapter 66); effective 6/10/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
<p>West Virginia 2015 HB 2931 (Continued) (Page 2 of 2)</p>	<p>Adds the following tryptamines to Schedule I: (7) 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT); (8) 4-hydroxy Diethyltryptamine (4-HO-DET); (9) 5- methoxy- N,N- diallyltryptamine (5-MeO-DALT); (10) 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT); (11) 4-hydroxy Diethyltryptamine (4-HO-DET).</p> <p>Adds the following substituted amphetamines to Schedule I: (1) 2-Fluoroamphetamine (2) 3-Fluoroamphetamine (3) 4-Fluoroamphetamine (4) 2-chloroamphetamine (5) 3-chloroamphetamine (6) 4-chloroamphetamine (7) 2-Fluoromethamphetamine (8) 3-Fluoromethamphetamine (9) 4-Fluoromethamphetamine (10) 4-chloromethamphetamine.</p>	<p>4/2/2015 – enacted (2015 Laws Chapter 66); effective 6/10/2015.</p>
<p>West Virginia 2015 SB 458</p>	<p>Adds ephedrine, pseudoephedrine and phenylpropanolamine to Schedule IV.</p>	<p>2/11/2015 – referred to Health and Human Resources Committee.</p>
<p>Wisconsin Controlled Substances Board 2.39</p>	<p>Naloxegol removed from Schedule II.</p>	<p>4/1/2015 – effective.</p>
<p>Wisconsin 2015 AB 224</p>	<p>Among many other provisions, removes Tetrahydrocannabinols from Schedule I.</p>	<p>5/19/2015 – read first time and referred to Committee on Criminal Justice and Public Safety.</p>

Yellow highlighted text indicates legislation that has been enacted into law.  
Red text indicates that the legislature presently is not in session.  
Blue text represents updates from the previous NAMS DL Bill Status Update.

<b>State and Bill Number</b>	<b>Description</b>	<b>Status/Date of Last Action</b>
Wyoming  2015 SF 16	<p>Adds the following hallucinogenic substance to Schedule I:  (1) 3,4-methylenedioxy-N-ethylcathinone [other names: ethylone].</p> <p>Adds the following synthetic cannabinoids to Schedule I:  (1) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide [other names: AB-CHMINACA];  (2) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone [other names: THJ-2201];  (3) 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester [other names: BB-22].</p> <p>Adds the following stimulants to Schedule I:  (1) 4-methyl-N-ethylcathinone [other names: 4-MEC; 2-(ethylamino)-1-(4-ethylphenyl)propan-1-one];  (2) 4-methyl-alpha-pyrrolidinopropiophenone [other names: 4-MePPP; MePPP; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one];  (3) Alpha-pyrrolidinopentiophenone [other names: alpha-PVP; alpha-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one];  (4) Butylone [other names: bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one];  (5) Pentedrone [other names: alpha-methylaminovalerophenone; 2-(methylamino)-1-phenylpentan-1-one];  (6) Pentylone [other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one];  (7) Naphyrone [other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one];  (8) Alpha-pyrrolidinobutiophenone [other names: alpha-PBP; 1-phenyl-2-(pyrrolidin-1-yl)butan-1-one].</p>	3/4/2015 – enacted (2015 Laws Chapter 136); effective 3/4/2015.

Yellow highlighted text indicates legislation that has been enacted into law.

Red text indicates that the legislature presently is not in session.

Blue text represents updates from the previous NAMSDL Bill Status Update.